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SCIENTIFIC OPINION  
Scientific Opinion on Flavouring Group Evaluation 23, Revision 3 
(FGE.23Rev3): 
Aliphatic, alicyclic and aromatic ethers including anisole derivatives from 
chemical groups 15, 16, 22, 26 and 301 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)2, 3  
European Food Safety Authority (EFSA), Parma, Italy 
 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European 
Food Safety Authority was requested to evaluate 20 flavouring substances in the Flavouring Group 
Evaluation 23, Revision 3, using the Procedure in Commission Regulation (EC) No 1565/2000. None 
of the substances were considered to have genotoxic potential. The substances were evaluated through 
a stepwise approach (the Procedure) that integrates information on structure-activity relationships, 
intake from current uses, toxicological threshold of concern, and available data on metabolism and 
toxicity. The Panel concluded that all 20 substances [FL-no: 02.247, 02.248, 03.008, 03.011, 03.012, 
03.015, 03.016, 03.020, 03.022, 03.024, 04.059, 04.067, 04.068, 04.069, 04.075, 04.079, 04.084, 
08.127, 09.687 and 13.200] do not give rise to safety concerns at their levels of dietary intake, 
estimated on the basis of the MSDI approach. Besides the safety assessment of these flavouring 
substances, the specifications for the materials of commerce have also been considered. Specifications 
including complete purity criteria and identity for the materials of commerce have been provided for 
all 20 candidate substances. 
© European Food Safety Authority, 2011 
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SUMMARY 
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was asked to evaluate one flavouring substance in the 
Flavouring Group Evaluation 23, Revision 3 (FGE.23Rev3), using the Procedure as referred to in the 
Commission Regulation (EC) No 1565/2000. The flavouring substance belongs to chemical group 16, 
Annex I of the Commission Regulation (EC) No 1565/2000. 
The present Flavouring Group Evaluation therefore deals with 20 candidate substances, which are 
aliphatic, alicyclic and aromatic ethers including anisole derivatives. Four of the candidate substances 
are aliphatic ethers, two are alicyclic ethers, three are alicyclic hydrocarbons with an ether side chain, 
two are ethers containing a benzene moiety, eight are phenol ethers and one is a naphthol ether. 
Six of the 20 candidate substances possess one or more chiral centres and three can exist as 
geometrical isomers. For these six substances the stereoisomeric composition has been specified. 
Three candidate substances can exist as geometrical isomers, the isomers have been specified.  
Two of the flavouring substances are classified into structural class I, seven are classified into 
structural class II and 11 are classified into structural class III according to the decision tree approach 
presented by Cramer et al., 1978. 
Ten of the substances in the present group have been reported to occur naturally in a wide range of 
food items. 
In its evaluation, the Panel as a default used the “Maximised Survey-derived Daily Intake” (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe. However, when the 
Panel examined the information provided by the European Flavour Industry on the use levels in 
various foods, it appeared obvious that the MSDI approach in a number of cases would grossly 
underestimate the intake by regular consumers of products flavoured at the use level reported by the 
Industry, especially in those cases where the annual production values were reported to be small. In 
consequence, the Panel had reservations about the data on use and use levels provided and the intake 
estimates obtained by the MSDI approach.  
In the absence of more precise information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” 
(mTAMDI) approach based on the normal use levels reported by Industry. In those cases where the 
mTAMDI approach indicated that the intake of a flavouring substance might exceed its corresponding 
threshold of concern, the Panel decided not to carry out a formal safety assessment using the 
Procedure. In these cases the Panel requires more precise data on use and use levels. 
According to the default MSDI approach, the 20 flavouring substances in this group have intakes in 
Europe from 0.011 to 49 micrograms/capita/day, which are below the threshold of concern value for 
structural class I of 1800 micrograms/person/day, for structural class II of 540 micrograms/person/day 
and for structural class III of 90 micrograms/person/day. 
The genotoxic potential of this group of flavouring substances cannot be fully assessed as it is now. 
However, the data available do not indicate a genotoxic potential and therefore do not preclude their 
evaluation via the Procedure. 
According to the available data on supporting substances, it is expected that all 20 candidate 
substances in this group would be metabolised to innocuous products at the reported levels of intake as 
flavouring substances.  
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It was noted that no repeated dose toxicity studies have been provided for any of the candidate 
substances and only a few studies were available on supporting substances. However, these 
toxicological data were consistent with the conclusions in the present Flavouring Group Evaluation 
using the Procedure. 
It was concluded that on the basis of the default MSDI approach the 20 candidate substances would 
not give rise to safety concerns at estimated levels of intake arising from their use as flavouring 
substances.  
When the estimated intakes were based on the mTAMDI approach they were 3200 
micrograms/person/day for the two flavouring substances belonging to structural class I and for five of 
the seven flavouring substances belonging to structural class II. The mTAMDI for the remaining two 
flavouring substances from class II are 3500 and 14000 micrograms/person/day. These intakes are 
above the threshold of concern for structural class I of 1800 micrograms/person/day and for structural 
class II of 540 micrograms/person/day. For 10 of the 11 candidate substances belonging to structural 
class III the mTAMDI are 860, 2500, 3200 or 3900 microgram/person/day, which are above the 
threshold of concern of 90 micrograms/person/day. For one substance from structural class III the 
mTAMDI of 58 micrograms/person/day is below the threshold. This substance is also expected to be 
metabolised to innocuous products.  
Thus, for 19 of the 20 flavouring substances considered in this Opinion the intakes, estimated on the 
basis of the mTAMDI, exceed the relevant threshold for their structural class, to which the flavouring 
substances have been assigned. Therefore, for these 19 substances, more reliable exposure data are 
required. On the basis of such additional data, these flavouring substances should be reconsidered 
along the steps of the Procedure. Following this procedure additional toxicological data might become 
necessary. 
In order to determine whether the conclusion for the 20 candidate substances can be applied to the 
materials of commerce, it is necessary to consider the available specifications. Specifications including 
purity criteria and identity for the materials of commerce have been provided for all 20 flavouring 
substances. 
For all the 20 substances [FL-no: 02.247, 02.248, 03.008, 03.011, 03.012, 03.015, 03.016, 03.020, 
03.022, 03.024, 04.059, 04.067, 04.068, 04.069, 04.075, 04.079, 04.084, 08.127, 09.687 and 13.200] 
the Panel concluded that they would present no safety concern at the estimated levels of intake based 
on the MSDI approach. 
KEYWORDS 
Flavourings, food safety, aliphatic, alicyclic, aromatic, ethers, FGE.23. 
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 
Procedure for the establishment of a list of flavouring substances the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2009/163/EC (EC, 
2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 
divided into 34 chemical groups. Substances within a group should have some metabolic and 
biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999a). For the submission of data by the 
manufacturer, deadlines have been established by Commission Regulation (EC) No 622/2002 (EC, 
2002b).  
The Flavouring Group Evaluation (FGE) is revised to include substances for which data were 
submitted after the deadline as laid down in Commission Regulation (EC) No 622/2002 and to take 
into account additional information that has been made available since the previous Opinion on this 
FGE.  
The Revision also includes newly notified substances belonging to the same chemical groups 
evaluated in this FGE. 
After the completion of the evaluation programme the Union List of flavouring substances for use in 
or on foods in the EU shall be adopted (Article 5 (1) of Regulation (EC) No 2232/96) (EC, 1996a). 
HISTORY OF THE EVALUATION  
The Flavouring Group Evaluation 23, FGE.23 dealt with 14 aliphatic, alicyclic and aromatic 
ethers including anisole derivatives. 
The first Revision of FGE.23, FGE.23Rev1, included the assessment of four additional candidate 
substances [FL-no: 02.247, 02.248, 03.022 and 08.127]. No toxicity or metabolism data were 
available, except for one new substance [FL-no: 02.248], for which two in vitro genotoxicity studies 
have been submitted. Additional information on stereoisomeric composition on two substances [FL-
no: 03.008 and 03.020] has become available since the first FGE was published. 
The second Revision of FGE.23, FGE.23Rev2, included the assessment of one additional candidate 
substance [FL-no: 03.024]. No toxicity and/or metabolism data were provided by Industry for this 
substance. A search in open literature for this substance did not provide any further data on toxicity or 
metabolism. Since the publication of FGE.23Rev1 information on stereoisomeric composition and a 
identity test has been provided by EFFA on the following four substances: [FL-no: 02.247, 02.248, 
03.022 and 08.127]. 
FGE Opinion 
adopted by 
EFSA 
Link No. of 
candidate 
substance
s 
FGE.23 29 November 
2006 
http://www.efsa.europa.eu/en/science/afc/afc_opinions/ej417_fge23.html 14 
FGE.23Rev1 27 September 
2007 
http://www.efsa.europa.eu/EFSA/efsa_locale-
1178620753812_1211902124677.htm 
18 
FGE.23Rev2 29 September 
2010 
http://www.efsa.europa.eu/en/efsajournal/pub/1848.htm 
 
19 
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FGE.23Rev3 28 September 
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The present revision of FGE.23, FGE.23Rev3, includes the assessment of one additional candidate 
substance 5-isopropyl-2,6-diethyl-2-methyltetrahydro-2H-pyran [FL-no: 13.200]. No new metabolism 
data were provided by Industry for this substance. However, for the supporting substance [FL-no: 
13.037] in vitro genotoxicity study was provided. A search in open literature for [FL-no: 13.200] did 
not provide any further data on toxicity or metabolism. 
Since the publication of FGE.23Rev2 information on stereoisomeric composition and use levels has 
been provided by EFFA on the following two substances: [FL-no: 02.248 and 03.022] (EFFA, 2011a; 
Flavour Industry, 2011b). 
TERMS OF REFERENCE 
The European Food Safety Authority (EFSA) is requested to carry out a risk assessment on flavouring 
substances in the register (Commission decision 1999/217/EC), according to Commission Regulation 
(EC) No 1565/2000 (EC, 2000a), prior to their authorisation and inclusion in the Union list 
(Regulation (EC) No 1334/2008). In addition, the Commission requested EFSA to evaluate newly 
notified flavouring substances, where possible, before finalising the evaluation programme. The 
evaluation programme was finalised at the end of 2009. 
After the finalisation of the evaluation programme, in their letter of the 12th April 2010, the 
Commission requested EFSA to carry out an evaluation of the flavouring substance 5-isopropyl-2,6-
diethyl-2-methyltetrahydro-2H-pyran [FL-no: 13.200], also according to Commission Regulation (EC) 
No 1565/2000 (EC, 2000a). 
ASSESSMENT 
1. Presentation of the Substances in Flavouring Group Evaluation 23, Revision 3 
1.1. Description 
The present Flavouring Group Evaluation 23, Revision 3 (FGE.23Rev3), using the Procedure as 
referred to in the Commission Regulation (EC) No 1565/2000 (The Procedure – shown in schematic 
form in Annex I of this FGE), deals with 20 aliphatic, alicyclic or aromatic ethers. These 20 flavouring 
substances (candidate substances) belong to the chemical groups 15, 16, 22, 26 and 30, Annex I of 
Commission Regulation (EC) No 1565/2000 (EC, 2000a). 
The 20 candidate substances under consideration in the present evaluation are listed in Table 1, as well 
as their chemical Register names, FLAVIS- (FL-), Chemical Abstract Service- (CAS-), Council of 
Europe- (CoE-) and Flavor and Extract Manufactures Association- (FEMA-) numbers, structures and 
specifications. Four of the candidate substances are aliphatic ethers [FL-no: 03.015, 03.016, 03.022 
and 03.024], two are alicyclic ethers [FL-no: 03.008 and 13.200], three are alicyclic hydrocarbons 
with ether side chain [FL-no: 02.247, 02.248 and 03.020] of which [FL-no: 02.248] also has an acetal 
moiety, two are ethers containing a benzene moiety [FL-no: 03.011 and 03.012], eight are phenol 
ethers [FL-no: 04.059, 04.067, 04.068, 04.069, 04.079, 04.084, 08.127 and 09.687] and one is a 
naphthol ether [FL-no: 04.075].  
The outcome of the safety evaluations are summarised in Table 2a.   
The hydrolysis products of the candidate esters and the acetal are listed in Table 2b. 
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The 20 candidate substances are structurally related to 28 flavouring substances (supporting 
substances) evaluated at the 51st JECFA meeting (JECFA, 2000a) in the group of “Aliphatic acyclic 
and alicyclic terpenoid tertiary alcohols and structurally related substances”, evaluated at the 59th 
JECFA meeting (JECFA, 2002c) in the group of “Phenethyl alcohol, aldehyde, acid and related acetals 
and esters” and evaluated at the 61st JECFA meeting (JECFA, 2004a) in the group of “Aliphatic and 
aromatic ethers”. These substances, with the respective structural formulas, FEMA, CoE and CAS 
register numbers, evaluation status by the Scientific Committee on Food (SCF), the JECFA and the 
CoE, and the European Maximised Survey-derived Daily Intake (MSDI) values, are listed in Table 3. 
1.2. Stereoisomers 
It is recognised that geometrical and optical isomers of substances may have different properties. Their 
flavour may be different, they may have different chemical properties resulting in possible variability 
in their absorption, distribution, metabolism, elimination and toxicity. Thus, information must be 
provided on the configuration of the flavouring substance, i.e. whether it is one of the 
geometrical/optical isomers, or a defined mixture of stereoisomers. The available specifications of 
purity will be considered in order to determine whether the safety evaluation carried out for candidate 
substances for which stereoisomers may exist can be applied to the material of commerce. Flavouring 
substances with different configurations should have individual chemical names and codes (CAS 
number, FLAVIS number etc.). 
Two flavouring substances possess one chiral centre [FL-no: 03.020 and 08.127], three possess three 
chiral centres [FL-no: 02.247, 03.008 and 13.200] and one possesses five chiral centres [FL-no: 
02.248]. The steroisomeric composition has been specified for all these substances (see Table 1).  
Due to the presence and the position of double bonds three of the substances [FL-no: 03.015, 03.022 
and 03.024] can exist as geometrical isomers. The chemical Register name and the CASrn provided 
specify the configuration of the double bond for [FL-no: 03.015 and 03.024]. For [FL-no: 03.022] 
Industry has informed that it occurs as a mixture of E- & Z-isomers with at least 40 % of each (EFFA, 
2011a) (see Table 1). 
1.3. Natural Occurrence in Food 
Ten candidate substances in the present group have been reported to occur in spices (ginger, savory, 
vanilla, thyme, clary sage, marjoram), dried bonito, tea, juice (grapefruit, lemon), lychee fruit, 
starfruit, heated blackberry, heated beans, cape gooseberry, mushroom, smoked oily fish, brandy, rum 
and wine (TNO, 2000). Quantitative data on the natural occurrence in foods have been reported for 
three of these substances in the present Flavouring Group Evaluation. 
These reports include: 
• Ethyl geranyl ether [FL-no: 03.015]: 0.0001 mg/kg in grapefruit juice, up to 0.2 mg/kg in 
lychee 
• Carvacryl methyl ether [FL-no: 04.059]: 800 mg/kg in ginger, up to 5000 mg/kg in savory, up 
to 14400 mg/kg in thyme 
• 1,2,3-Trimethoxybenzene [FL-no: 04.084]: 3.8 mg/kg in dried bonito, 20 mg/kg in tea. 
 
According to TNO (TNO, 2000; TNO, 2011) 10 of the substances have not been reported to occur 
naturally in any food items. These 10 substances are l-menthoxyethanol [FL-no: 02.247], vanillin 3-(l-
menthoxy)propane-1,2-diol acetal [FL-no: 02.248], 2-acetoxy-1,8-cineole [FL-no: 03.008], alpha-
terpinyl methyl ether [FL-no: 03.020], 1-methoxy-1-decene [FL-no: 03.022], digeranylether [FL-no: 
03.024], 1-ethoxy-2-methoxybenzene [FL-no: 04.067], 2-(4-methoxyphenoxy)propionic acid [FL-no: 
Flavouring Group Evaluation 23, Revision 3
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08.127], 2-phenoxyethyl butyrate [FL-no: 09.687] and 5-isopropyl-2,6-diethyl-2-methyltetrahydro-
2H-pyran [FL-no: 13.200].  
2. Specifications 
Purity criteria for the 20 substances have been provided by the flavouring industry (EFFA, 2003k; 
EFFA, 2004af; EFFA, 2004j; Flavour Industry, 2006a; Flavour Industry, 2009g; Flavour Industry, 
2010i) (Table 1). 
Judged against the requirements in Annex II of Commission Regulation EC No 1565/2000 (EC, 
2000), the information is adequate for all 20 candidate substances (see Section 1.2 and Table 1). 
3. Intake Data 
Annual production volumes of the flavouring substances as surveyed by the Industry can be used to 
calculate the “Maximised Survey-derived Daily Intake” (MSDI) by assuming that the production 
figure only represents 60 % of the use in food due to underreporting and that 10 % of the total EU 
population are consumers (SCF, 1999a). 
However, the Panel noted that due to year-to-year variability in production volumes, to uncertainties 
in the underreporting correction factor and to uncertainties in the percentage of consumers, the 
reliability of intake estimates on the basis of the MSDI approach is difficult to assess. 
The Panel also noted that in contrast to the generally low per capita intake figures estimated on the 
basis of this MSDI approach, in some cases the regular consumption of products flavoured at use 
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In 
such cases, the human exposure thresholds below which exposures are not considered to present a 
safety concern might be exceeded. 
Considering that the MSDI model may underestimate the intake of flavouring substances by certain 
groups of consumers, the SCF recommended also taking into account the results of other intake 
assessments (SCF, 1999a). 
One of the alternatives is the “Theoretical Added Maximum Daily Intake” (TAMDI) approach, which 
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for flavourable 
beverages and foods in general, with exceptional levels for particular foods. This method is regarded 
as a conservative estimate of the actual intake by most consumers because it is based on the 
assumption that the consumer regularly eats and drinks several food products containing the same 
flavouring substance at the upper use level. 
One option to modify the TAMDI approach is to base the calculation on normal rather than upper use 
levels of the flavouring substances. This modified approach is less conservative (e.g., it may 
underestimate the intake of consumers being loyal to products flavoured at the maximum use levels 
reported) (EC, 2000a). However, it is considered as a suitable tool to screen and prioritise the 
flavouring substances according to the need for refined intake data (EFSA, 2004a). 
3.1. Estimated Daily per Capita Intake (MSDI Approach) 
The intake estimation is based on the Maximised Survey-derived Daily Intake (MSDI) approach, 
which involves the acquisition of data on the amounts used in food as flavourings (SCF, 1999a). These 
data are derived from surveys on annual production volumes in Europe. These surveys were conducted 
in 1995 by the International Organization of the Flavour Industry, in which flavour manufacturers 
reported the total amount of each flavouring substance incorporated into food sold in the EU during 
Flavouring Group Evaluation 23, Revision 3
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the previous year (IOFI, 1995). The intake approach does not consider the possible natural occurrence 
in food. 
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is 
consumed by 10 % of the population4 (Eurostat, 1998). This is derived for candidate substances from 
estimates of annual volume of production provided by Industry and incorporates a correction factor of 
0.6 to allow for incomplete reporting (60 %) in the Industry surveys (SCF, 1999a). 
In the present Flavouring Group Evaluation 23, Revision 3 (FGE.23Rev3) the total annual volume of 
production of the 20 candidate substances for use as flavouring substances in Europe has been 
reported to be approximately 750 kg (EFFA, 2003l; EFFA, 2004af; EFFA, 2004k; Flavour Industry, 
2006a; Flavour Industry, 2009g; Flavour Industry, 2010i) and for 28 supporting substances 
approximately 34000 kg (JECFA, 2000a; JECFA, 2002c; JECFA, 2004a). 
On the basis of the annual volumes of production reported for the 20 candidate substances, the daily 
per capita intakes for each of these flavourings have been estimated (Table 2a). Approximately 96 % 
of the total annual volume of production for the candidate substances is accounted for by seven 
flavourings: 1-methoxyethanol [FL-no: 02.247], benzyl methyl ether [FL-no: 03.011], alpha-terpinyl 
methyl ether [FL-no: 03.020], 1-methoxy-1-decene [FL-no: 03.022], digeranyl ether [FL-no: 03.024], 
carvacryl methyl ether [FL-no: 04.059] and 5-isopropyl-2,6-diethyl-2-methyltetrahydro-2H-pyran 
[FL-no: 13.200]. The estimated daily per capita intakes of these candidate substances from use as a 
flavouring substance are 15, 1.9, 4.1, 6.1, 49, 1.2 and 12 microgram, respectively. For each of the 
remaining 13 substances the estimated daily per capita intake is less than 0.7 microgram (Table 2a). 
3.2. Intake Estimated on the Basis of the Modified TAMDI (mTAMDI) 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 
is based on the approach used by SCF up to 1995 (SCF, 1995). 
The assumption is that a person may consume a certain amount of flavourable foods and beverages per 
day. 
For the present evaluation of the 20 candidate substances, information on food categories and normal 
and maximum use levels5,6,7 were submitted, by the Flavour Industry (EFFA, 2003k; EFFA, 2004af; 
EFFA, 2004j; EFFA, 2007a; Flavour Industry, 2006a; Flavour Industry, 2008a; Flavour Industry, 
2009g; Flavour Industry, 2010i;  Flavour Industry, 2011b).  
The 20 candidate substances, for which normal and maximum use levels were submitted by Industry, 
are used in flavoured food products divided into the food categories, outlined in Annex III of the 
Commission Regulation (EC) No 1565/2000 (EC, 2000a), as shown in Table 3.1. For the present 
calculation of mTAMDI, the reported normal use levels were used. In the case where different use 
levels were reported for different food categories the highest reported normal use level was used. 
                                                     
 
4 EU figure 375 millions. This figure relates to EU population at the time for which production data are 
available, and is consistent (comparable) with evaluations conducted prior to the enlargement of the EU. No 
production data are available for the enlarged EU. 
5 ”Normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th percentile 
of reported usages (EFFA, 2002i). 
6 The normal and maximum use levels in different food categories (EC, 2000) have been extrapolated from 
figures derived from 12 model flavouring substances (EFFA, 2004e). 
7 The use levels from food category 5 “Confectionery” have been inserted as default values for food category 
14.2 “Alcoholic beverages” for substances for which no data have been given for food category 14.2 (EFFA, 
2007a). 
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Table 3.1 Use of Candidate Substances 
Food 
category 
Description Flavourings used 
01.0 Dairy products, excluding products of category 2 All except [FL-no: 
02.248 and 03.024] 
02.0 Fats and oils, and fat emulsions (type water-in-oil) All except [FL-no: 
03.024] 
03.0 Edible ices, including sherbet and sorbet All except [FL-no: 
02.248] 
04.1 Processed fruits All except [FL-no: 
02.248 and 03.024] 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and 
legumes), and nuts & seeds 
Only [FL-no:02.248, 
03.022 and 13.200] 
05.0 Confectionery All  
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses 
& legumes, excluding bakery 
All except [FL-no: 
03.022 and 03.024] 
07.0 Bakery wares All except [FL-no: 
03.024] 
08.0 Meat and meat products, including poultry and game All except [FL-no: 
02.248, 03.024 and 
13.200] 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  All except [FL-no: 
03.024 and 13.200] 
10.0 Eggs and egg products Only [FL-no: 13.200] 
11.0 Sweeteners, including honey Only [FL-no: 13.200] 
12.0 Salts, spices, soups, sauces, salads, protein products etc. All except [FL-no: 
03.024] 
13.0 Foodstuffs intended for particular nutritional uses All except [FL-no: 
02.248, 03.022, 
03.024 and 13.200] 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products All  
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts All  
15.0 Ready-to-eat savouries All except [FL-no: 
02.248, 03.008, 
03.024 and 13.200] 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not 
be placed in categories 1 – 15 
All except [FL-no: 
13.200] 
 
According to the Flavour Industry the normal use levels for the 20 candidate substances, are in the 
range of 0.0015 to 70 mg/kg food and the maximum use levels are in the range of 0.0125 to 100 
mg/kg (EFFA, 2003k; EFFA, 2004af; EFFA, 2004j; EFFA, 2007a; Flavour Industry, 2006a; Flavour 
Industry, 2008a; Flavour Industry, 2009g; Flavour Industry, 2010i; Flavour Industry, 2011b) (see 
Table II.1.2, Appendix II).  
The mTAMDI values for the 20 candidate substances from structural class I, II and III (see Section 5) 
are in the range of 58 to 14000 micrograms/person/day. 
For detailed information on use levels and intake estimations based on the mTAMDI approach, see 
Section 6 and Annex II. 
4. Absorption, Distribution, Metabolism and Elimination 
The candidate substances are examples of aliphatic, alicyclic or aromatic ethers. On the basis of their 
structure they can be divided into seven subgroups:  
1) aliphatic ethers [FL-no: 03.015, 03.016 and 03.022],  
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2) alicyclic ethers [FL-no: 03.008 and 13.200],  
3) alicyclic hydrocarbons with an ether side chain [FL-no: 02.247, 02.248 and 03.020] of which [FL-
no: 02.248] also has an acetal moiety,  
4) benzyl ethers [FL-no: 03.011 and 03.012], 
5) phenol ethers [FL-no: 04.059, 04.067, 04.068, 04.069, 04.079, 04.084, 08.127 and 09.687],  
6) naphthol ethers [FL-no: 04.075] and  
7) long chain aliphatic ethers [FL-no: 03.024] (see Table 4.1). 
No data on absorption, distribution, metabolism or elimination are reported for 19 of the 20 candidate 
substances.  
According to the available data on supporting substances, the simple aliphatic ethers in subgroup 1 
[FL-no: 03.015, 03.016 and 03.022], the cyclic ethers in subgroup 2 [FL-no: 03.008 and 13.200], the 
cyclic hydrocarbons with ether side chain in subgroup 3 [FL-no: 02.247, 02.248 and 03.020] of which 
[FL-no: 02.248] also has an acetal moiety, the benzyl ethers in subgroup 4 [FL-no: 03.011 and 03.012] 
and the phenolic ethers in subgroup 5 [FL-no: 04.059, 04.067, 04.068, 04.069, 04.079, 04.084, 08.127 
and 09.687] and the long chain aliphatic ether in subgroup 7) [FL-no: 03.024] are all expected to be 
rapidly absorbed from the gastrointestinal tract and excreted in the exhaled air as CO2 and as polar 
metabolites in the urine.  
After absorption, the supporting substance, beta-naphthyl methyl ether [FL-no: 04.033], representative 
for the naphthol ether in subgroup 6 [FL-no: 04.075] is hydroxylated and excreted as a glucuronide. 
Concerning their biotransformation, it can be expected that the straight-chain aliphatic ethers included 
in subgroup 1 may undergo O-dealkylation in vivo, catalysed by cytochrome P450 to yield the 
corresponding alcohol and aldehyde that subsequently undergo complete oxidation in the fatty acid 
pathway and tricarboxylic acid cycle. The demethylated product of 1-methoxy-1-decene [FL-no: 
03.022] is an enol, which will rearrange to the aldehyde, which subsequently can be oxidised to the 
carboxylic acid. 
The candidate substances, 2-acetoxy-1,8-cineole [FL-no: 03.008] and 5-isopropyl-2,6-diethyl-2-
methyltetrahydro-2H-pyran [FL-no: 13.200], within subgroup 2 (alicyclic ether), on the basis of 
information on representative supporting substances, may be anticipated to undergo ring-
hydroxylation by P450, conjugation with glucuronic acid followed by excretion in the urine. 
The available data on alpha-terpineol [FL-no: 02.014] and terpenoid tertiary alcohols, taken as 
supporting substances, suggest that the substance in subgroup 3 [FL-no: 03.020] would be metabolised 
by P450 isoenzymes to yield polar hydroxylated metabolites, which are conjugated to 
form glucuronic acid conjugates and excreted or are further oxidised and excreted. Cleavage of the 
ether is a minor metabolic pathway (JECFA, 1999a). The acetal moiety in vanillin 3-(l-
menthoxy)propane-1,2-diol acetal [FL-no: 02.248] is shown to be hydrolysed, resulting in the 
formation of the corresponding ether and vanillin. It is expected that the alcohol group in this ether 
subsequently are oxidised and that the carboxylic acid(s) are excreted as a conjugate or excreted as the 
acid itself. Similarly, l-menthoxy ethanol [FL-no: 02.247] is anticipated to be oxidised to the 
corresponding carboxylic acid and excreted. 
The benzyl ethers found in subgroup 4 [FL-no: 03.011 and 03.012] are expected to be metabolised in a 
similar way to mono-alkyl derivatives of benzene. It is generally accepted that mono-alkyl derivatives 
of benzene are metabolised by undergoing biotransformation of the side chain to produce alcohols and 
carboxylic acids which are eliminated in the urine as conjugates of glucuronic acid or glycine 
(Williams, 1959a). 
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The candidate aromatic ethers in subgroup 5 [FL-no: 04.059, 04.067, 04.068, 04.069, 04.079, 04.084, 
08.127 and 09.687] are expected to be metabolised by ring-hydroxylation (mainly in the para position, 
cleavage of the methyl ether (O-demethylation) and/or oxidation of the ring substituents depending on 
the position of substituents. These products would then be expected to be conjugated primarily with 
glucuronic acid and to a lesser extent sulphate or glycine and excreted in the urine. 2-(4-
Methoxyphenoxy)propionic acid [FL-no: 08.127] is expected to be excreted after conjugation or 
alternatively excreted as the unconjugated acid. 
Table 4.1. Candidate Substances Divided into Subgroups of Related Chemical Structures 
FL-no EU Register name Structural formula  
1 Aliphatic Ethers 
03.015 Ethyl geranyl ether 
O
 
03.016 Hexyl methyl ether O  
03.022 1-Methoxy-1-decene   O  
2 Alicyclic Ethers 
03.008 2-Acetoxy-1,8-cineole 
O
O
O
 
13.200 5-Isopropyl-2,6-diethyl-2-methyltetrahydro-
2H-pyran 
O
 
3 Alicyclic Hydrocarbons with Ether Side Chain
02.247 l-Menthoxyethanol 
O
OH
 
02.248 Vanillin 3-(l-menthoxy)propane-1,2-diol 
acetal 
O
O
O
OHO
 
03.020 alpha-Terpinyl methyl ether  
O
 
4 Benzyl Ethers 
03.011 Benzyl methyl ether O  
03.012 Benzyl octyl ether O  
5 Phenol Ethers 
04.059 Carvacryl methyl ether 
O
 
04.067 1-Ethoxy-2-methoxybenzene O
O
 
04.068 1-Ethoxy-4-methoxybenzene 
O
O  
04.069 1-Ethyl-4-methoxybenzene 
O
 
04.079 Methyl 4-methoxybenzyl ether O
O
 
04.084 1,2,3-Trimethoxybenzene 
O O
O  
08.127 2-(4-Methoxyphenoxy)propionic acid O
O
OH
O
 
09.687 2-Phenoxyethyl butyrate 
O
O
O  
6 Naphthol Ethers 
04.075 1-Methoxynaphthalene 
O
 
7 Long Chain Aliphatic Ether 
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Table 4.1. Candidate Substances Divided into Subgroups of Related Chemical Structures 
FL-no EU Register name Structural formula  
03.024 Digeranyl ether 
O
 
 
Metabolism data are available on the supporting substance 2-methoxynaphtalene [FL-no: 04.074] from 
subgroup 6, which is shown to be excreted as a glucuronide (Williams, 1959a). 
No data are available on the absorption, distribution and excretion of the substance in subgroup 7 or 
any supporting substances but as with the other substances in this FGE, digeranyl ether would be 
expected to be rapidly absorbed from the gastrointestinal tract and excreted as polar metabolites in the 
urine and in the exhaled air as CO2.  
Whilst no metabolism data have been found for the candidate substance in subgroup 7, digeranyl ether 
[FL-no: 03.024], data are available on substances that are supporting for the metabolism of longer 
chain ethers. Dealkylation of ethers becomes less likely as the chain length increases and ω-oxidation 
is more likely to occur (Tsuji et al., 1978). For geraniol, next to other pathways of metabolism related 
to the presence of a free hydroxyl-group, ω-oxidation has also been described and this would result in 
metabolism to innocuous products. As digeranyl ether contains no free hydroxyl group like geraniol, 
the other pathways for metabolism of geraniol are not available for digeranyl ether and therefore ω-
oxidation is more likely to occur. It would be expected that following ω-oxidation, the metabolites 
would be conjugated with glucuronide and excreted in the urine. 
It can be anticipated that all 20 candidate substances [FL-no: 02.247, 02.248, 03.008, 03.011, 03.012, 
03.015, 03.016, 03.020, 03.022, 03.024, 04.059, 04.067, 04.068, 04.069, 04.075, 04.079, 04.084, 
08.127, 09.687 and 13.200] are metabolised to innocuous products. Although saturation of some 
metabolic pathways have been described, it occurs at high doses, unlikely to be reached by the 
candidate substances when used as flavouring substances at the present level of intake. 
A more detailed discussion of the metabolism of the candidate substances in this evaluation is 
provided in Annex III. 
5. Application of the Procedure for the Safety Evaluation of Flavouring Substances 
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach. 
Where the mTAMDI approach indicates that the intake of a flavouring substance might exceed its 
corresponding threshold of concern, a formal safety assessment is not carried out using the Procedure. 
In these cases the Panel requires more precise data on use and use levels. For comparison of the intake 
estimations based on the MSDI approach and the mTAMDI approach, see Section 6. 
For the safety evaluation of the 20 candidate substances from chemical groups 15, 16, 22, 26 and 30 
the Procedure as outlined in Annex I was applied, based on the MSDI approach. The stepwise 
evaluations are summarised in Table 2a. 
Step 1 
Using the decision tree approach presented by Cramer et al., two of the candidate substances [FL-no: 
04.059 and 04.084] were classified into structural class I, seven [FL-no: 03.008, 03.011, 03.012, 
03.015, 03.016, 03.024 and 04.079] into structural class II and 11 substances [FL-no: 02.247, 02.248, 
03.020, 03.022, 04.067, 04.068, 04.069, 04.075, 08.127, 09.687 and 13.200] into structural class III 
(Cramer et al., 1978). 
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Step 2 
On the basis of the metabolism information available all 20 candidate substances [FL-no: 02.247, 
02.248, 03.008, 03.011, 03.012, 03.015, 03.016, 03.020, 03.022, 03.024, 04.059, 04.067, 04.068, 
04.069, 04.075, 04.079, 04.084, 08.127, 09.687 and 13.200] can be predicted to be metabolised to 
innocuous products and therefore they will proceed along the A-side of the Procedure scheme. 
Step A3 
Two candidate substances [FL-no: 04.059 and 04.084] have been assigned to structural class I and 
have estimated European daily per capita intakes (MSDI) of 0.012 and 1.2 micrograms. The seven 
candidate substances [FL-no: 03.008, 03.011, 03.012, 03.015, 03.016, 03.024 and 04.079], which have 
been assigned to structural class II have estimated European daily per capita intake ranging from 
0.012 to 49 micrograms and the 11 candidate substances [FL-no: 02.247, 02.248, 03.020, 03.022, 
04.067, 04.068, 04.069, 04.075, 08.127, 09.687 and 13.200], which have been assigned to structural 
class III, have estimated European daily per capita intake ranging from 0.011 to 15 micrograms (Table 
6.1). These intakes are below the thresholds of concern of 1800, 540 and 90 micrograms/person/day 
for structural class I, II and III, respectively. 
Based on results of the safety evaluation sequence of the Procedure, these 20 candidate substances, 
proceeding via the A-side of the Procedure scheme, do not pose a safety concern when used as 
flavouring substances at the estimated levels of intake, based on the MSDI approach. 
6. Comparison of the Intake Estimations Based on the MSDI Approach and the mTAMDI 
Approach 
The estimated intakes for the 20 candidate substances in structural class I, II and III based on the 
mTAMDI range from 58 to 14000 micrograms/person/day. For 19 of these substances the mTAMDI is 
above the threshold of concern of 1800 micrograms/person/day for structural class I, of 540 
micrograms/person/day for structural class II and of 90 micrograms/person/day for structural class III. 
The estimated intake for [FL-no: 03.022] in structural class III based on the mTAMDI is 58 
micrograms/person/day, which is below the threshold of concern. This substance is also expected to be 
metabolised to innocuous products. 
For comparison of the intake estimates based on the MSDI approach and the mTAMDI approach see 
Table 6.1.  
For 19 candidate substances, for which the mTAMDI is above the threshold of concern further 
information is required. This would include more reliable intake data and then, if required, additional 
toxicological data. 
For comparison of the MSDI and mTAMDI values, see Table 6.1. 
 
Table 6.1 Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI 
(μg/capita/day) 
mTAMDI 
(μg/person/day) 
Structural 
class 
Threshold of concern 
(µg/person/day) 
04.059 Carvacryl methyl ether 1.2 3200 Class I 1800 
04.084 1,2,3-Trimethoxybenzene 0.012 3200 Class I 1800 
03.008 2-Acetoxy-1,8-cineole 0.037 3500 Class II 540 
03.011 Benzyl methyl ether 1.9 3200 Class II 540 
03.012 Benzyl octyl ether 0.24 3200 Class II 540 
03.015 Ethyl geranyl ether 0.012 3200 Class II 540 
03.016 Hexyl methyl ether 0.012 3200 Class II 540 
03.024 Digeranyl ether 49 14000 Class II 540 
04.079 Methyl-4-methoxybenzyl ether 0.61 3200 Class II 540 
02.247 l-Menthoxyethanol 15 3900 Class III 90 
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Table 6.1 Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI 
(μg/capita/day) 
mTAMDI 
(μg/person/day) 
Structural 
class 
Threshold of concern 
(µg/person/day) 
02.248 Vanillin 3-(l-menthoxy)propane-1,2-diol 
acetal 
0.61 2500 Class III 90 
03.020 alpha-Terpinyl methyl ether 4.1 3200 Class III 90 
03.022 1-Methoxy-1-decene 6.1 58 Class III 90 
04.067 1-Ethoxy-2-methoxybenzene 0.12 3200 Class III 90 
04.068 1-Ethoxy-4-methoxybenzene 0.67 3200 Class III 90 
04.069 1-Ethyl-4-methoxybenzene 0.073 3200 Class III 90 
04.075 1-Methoxynaphthalene 0.061 3200 Class III 90 
08.127 2-(4-Methoxyphenoxy)propionic acid 0.011 3200 Class III 90 
09.687 2-Phenoxyethyl butyrate 0.085 3900 Class III 90 
13.200 5-Isopropyl-2,6-diethyl-2-methyltetrahydro-
2H-pyran 
12 860 Class III 90 
7. Considerations of Combined Intakes from Use as Flavouring Substances 
Because of structural similarities of candidate and supporting substances, it can be anticipated that 
many of the flavourings are metabolised through the same metabolic pathways and that the 
metabolites may affect the same target organs. Further, in case of combined exposure to structurally 
related flavourings, the pathways could be overloaded. Therefore, combined intake should be 
considered. As flavourings not included in this FGE may also be metabolised through the same 
pathways, the combined intake estimates presented here are only preliminary. Currently, the combined 
intake estimates are only based on MSDI exposure estimates, although it is recognised that this may 
lead to underestimation of exposure. After completion of all FGEs, this issue should be readdressed. 
The total estimated combined daily per capita intake of structurally related flavourings is estimated by 
summing the MSDI for individual substances. 
On the basis of the reported annual production volumes in Europe (EFFA, 2003l; EFFA, 2004af; 
EFFA, 2004k; Flavour Industry, 2006a; Flavour Industry, 2009g; Flavour Industry, 2010i), the 
combined estimated daily per capita intakes as flavourings of the two candidate substances assigned to 
structural class I, of the seven candidate substances belonging to structural class II and of the 11 
candidate substances belonging to structural class III are 1.2, 52 and 39 micrograms, respectively. 
These values do not exceed the threshold of concern for substances belonging to structural class I of 
1800 micrograms/person/day, structural class II of 540 microgram/person/day and structural class III 
of 90 micrograms/person/day. 
The 20 candidate substances are structurally related to 28 supporting substances evaluated by the 
JEFCA at its 51st, 59th and 61st meeting (JECFA, 2000a; JECFA, 2002c; JECFA, 2004a). Based on 
reported production volumes, European per capita intakes (MSDI) could be estimated for the 28 
supporting substances.  
The total combined intake of the two candidate substances and 11 supporting substances from 
structural class I, is approximately 2800 micrograms/capita/day, which exceeds the threshold of 
concern for a compound belonging to structural class I of 1800 micrograms/capita/day. However, the 
major contribution to the total combined intake of flavouring substances assigned to structural class I 
(99 %) is provided by the two supporting substances, namely alpha-terpineol [FL-no: 02.014] (2600 
micrograms/capita/day) and terpineol acetate [FL-no: 09.830] (220 micrograms/capita/day). Terpineol 
acetate is anticipated to be hydrolysed to alpha-terpineol. These supporting substances were evaluated 
at the 51st JECFA meeting, where it was noted that although the combined intake exceeds the 
threshold for structural class I the substances are expected to be efficiently metabolised and would not 
saturate the metabolic pathways. The Panel agreed with this view and concluded that the combined 
intake of about 1.2 micrograms/capita/day for the candidate substances in structural class I is 
negligible compared to the combined intake of 2800 micrograms/capita/day of the supporting 
substances. 
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The total combined intake of the seven candidate substances and 10 supporting substances from 
structural class II, is approximately 1300 micrograms/capita/day, which exceeds the threshold of 
concern for a compound belonging to structural class II of 540 micrograms/person/day. More than 95 
% of the combined daily per capita intake of 1250 micrograms is provided by the supporting 
substance 1,8-cineole [FL-no: 03.001]. The supporting substances in structural class II were evaluated 
at the 61st JECFA meeting, where it was noted that although the combined intake exceeds the 
threshold, the substances are expected to be efficiently metabolised and would not saturate the 
metabolic pathways. The Panel agreed with this view and concluded that the combined intake of about 
52 micrograms/capita/day for the candidate substances in structural class II is negligible compared to 
the combined intake of 1250 micrograms/capita/day of the supporting substances. 
The total combined intake of the 11 candidate substances and seven supporting substances from 
structural class III for which production volumes in Europe were reported, is approximately 140 
micrograms/capita/day, which exceed the threshold of concern for a substance belonging to structural 
class III of 90 micrograms/capita/day. 
The supporting substances were evaluated by the JECFA at the 59th and 61st meetings, where it was 
noted that although the combined intake exceeds the threshold for the structural class, the substances 
are expected to be efficiently metabolised and would not saturate the metabolic pathways. The Panel 
agreed with this view and concluded that the combined intake of about 39 micrograms/capita/day for 
the candidate substances in structural class III is minor compared to the combined intake of about 100 
micrograms/capita/day of the supporting substances. 
Therefore, it can be concluded that the total combined intakes of the 20 candidate substances and 28 
supporting substances, including 1,8-cineole [FL-no: 03.001], alpha-terpineol [Fl-no: 02.014] and 
terpineol acetate [FL-no: 09.830], do not pose a safety concern. 
8. Toxicity 
8.1. Acute Toxicity 
Data are available for one of the candidate substances, ethyl-geranyl ether [FL-no: 03.015] with an 
oral LD50 value of more than 5000 mg/kg body weight (bw).  
Twenty of the 28 supporting substances were tested for acute toxicity in mice and/or rats. The oral 
LD50 values in mice and rats for the supporting substances range from 1000 mg/kg to 8000 mg/kg bw.  
Acute toxicity data are summarised in Annex IV, Table IV.1. 
8.2. Subacute, Subchronic, Chronic and Carcinogenicity Studies 
Data on subacute and subchronic toxicity are not available for any of the candidate substances but for 
10 of the 28 supporting substances of the present flavouring group.  
Repeated dose toxicity data are summarised in Annex IV, Table IV.2. 
8.3. Developmental / Reproductive Toxicity Studies 
Data on developmental toxicity and reproductive toxicity data are not available for any of the 
candidate substances but for two of the 28 supporting substances of the present flavouring group, 1,8-
cineole [FL-no: 03.001] and phenoxyacetic acid [FL-no: 08.049].  
The data available on developmental / reproductive toxicity do not preclude the evaluation of the 
candidate substances through the Procedure. 
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Developmental/reproductive toxicity data are summarised in Annex IV, Table IV.3. 
8.4. Genotoxicity Studies 
There are only five genotoxicity studies carried out on the candidate substances, 1,2,3-
trimethoxybenzene [FL-no: 04.084], vanillin 3-(l-menthoxy)propane-1,2-diol acetal [FL-no: 02.248] 
and 2,6-diethyl-5-isopropyl-2-methyltetrahydropyran [FL-no: 13.200]. One reverse mutation assay on 
[FL-no: 13.200] was considered valid and gave negative results both with and without metabolic 
activation (Thompson, 2008). The four remaining studies provided negative results but are of limited 
value. There have been a number of studies carried out on the supporting substances and these 
generally show that there is no cause for concern regarding their genotoxicity. Two in vitro studies 
produced positive results; these studies are described in greater detail below. None of the in vivo tests 
showed positive results. 
One of the in vitro genotoxicity studies (Heck et al., 1989) gave a positive result for the supporting 
substance 1-methoxy-4-methylbenzene [FL-no: 04.015] at a concentration of 188 microgram/ml. This 
study was an unscheduled DNA synthesis study. The test was carried out twice, but significant 
differences were seen between the initial results and the repeat assay and there was no explanation 
why these two results may have been different. Therefore, no definite conclusions could be drawn. 
A positive result was seen in a sister chromatid exchange study on the supporting substance 1,8-
cineole [FL-no: 03.001] (Galloway et al., 1987a). This study was only positive without S9 activation 
and at levels of 1,8-cineole of 200 and 500 microgram/ml, which induced cell cycle delay and 
therefore were cytotoxic. There are several other genotoxicity tests on this substance, including 
another sister chromatid exchange study (although the concentrations of test substance were much 
lower in this study), that have given negative results. In the light of these results in several 
genotoxicity studies at gene and chromosomal level the positive result in the sister chromatid 
exchange assay by Galloway (Galloway et al., 1987a) is considered not to be of relevance for the 
overall evaluation. It is therefore concluded that 1,8-cineole is not genotoxic. 
In summary the Panel concluded that the genotoxicity data available do not preclude the evaluation of 
the candidate substances through the Procedure. 
Genotoxicity data are summarised in Annex IV, Table IV.4 and Table IV.5. 
9. Conclusions 
The 20 candidate substances are aliphatic, alicyclic and aromatic ethers including anisole derivatives 
and belong to EU chemical groups 15, 16, 22, 26 and 30. Four of the candidate substances are 
aliphatic ethers, two are alicyclic ethers, three are alicyclic hydrocarbons with an ether side chain, two 
are ethers containing a benzene moiety, eight are phenol ethers and one is a naphthol ether. 
Six of the 20 candidate substances possess one or more chiral centres. For these six substances the 
stereoisomeric composition has been specified. Three candidate substances can exist as geometrical 
isomers, the isomers have been specified.  
Two of the flavouring substances are classified into structural class I, seven are classified into 
structural class II and 11 are classified into structural class III. 
Ten of the substances in the present group have been reported to occur naturally in a wide range of 
food items. 
According to the default MSDI approach, the 20 flavouring substances in this group have intakes in 
Europe from 0.011 to 49 micrograms/capita/day, which are below the threshold of concern value for 
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structural class I of 1800 micrograms/person/day, for structural class II of 540 micrograms/person/day 
and for structural class III of 90 micrograms/person/day. 
On the basis of the reported annual production in Europe (MSDI approach), the combined intake of 
the two candidate substances belonging to structural class I, of the seven candidate substances 
belonging to structural class II and of the 11 candidate substances belonging to structural class III, 
would result in combined intakes of approximately 1.2, 52 and 39 micrograms/capita/day, 
respectively. These values are lower than the thresholds of concern for structural class I, II or III 
substances. The estimated total combined intakes of the candidate and supporting substances (in 
Europe) are approximately 2800, 1300 and 140 micrograms/capita/day for structural class I, II and III 
substances, respectively.  
The combined daily per capita intake of 2800 microgram exceeds the threshold of concern of 1800 
microgram/person/day for structural class I substances. The supporting substances were evaluated at 
the 51st JECFA meeting, where it was noted that although the combined intake exceeds the threshold 
for structural class I the substances are expected to be efficiently metabolised and would not saturate 
the metabolic pathways. The Panel agreed with this view and concluded that the combined intake of 
about 1.2 micrograms/capita/day for the candidate substances in structural class I is negligible 
compared to the combined intake of 2800 micrograms/capita/day of the supporting substances. 
Likewise the total combined intake of the seven candidate substances and 10 supporting substances 
from structural class II is approximately 1300 micrograms/capita/day, which exceeds the threshold of 
concern for a compound belonging to structural class II of 540 micrograms/person/day. The 
supporting substances in structural class II were evaluated at the 61st JECFA meeting, where it was 
noted that although the combined intake exceeds the threshold, the substances are expected to be 
efficiently metabolised and would not saturate the metabolic pathways. The Panel agreed with this 
view and concluded that the combined intake of about 52 micrograms/capita/day for the candidate 
substances in structural class II is negligible compared to the combined intake of 1250 
micrograms/capita/day of the supporting substances.  
The total combined intake of candidate and supporting substances of structural class III is 140 
micrograms/capita/day, which is above the threshold of concern for structural class III of 90 
micrograms/capita/day. The supporting substances were evaluated by the JECFA at the 59th and 61st 
meetings, where it was noted that although the combined intake exceeds the threshold for the 
structural class, the substances are expected to be efficiently metabolised and would not saturate the 
metabolic pathways. The Panel agreed with this view and concluded that the combined intake of about 
39 micrograms/capita/day for the candidate substances in structural class III is minor compared to the 
combined intake of 100 micrograms/capita/day of the supporting substances. 
The genotoxic potential of this group of flavouring substances cannot be fully assessed as it is now. 
However, the data available do not indicate a genotoxic potential and therefore do not preclude their 
evaluation via the Procedure. 
According to the available data on supporting substances, it is expected that all 20 candidate 
substances in this group [FL-no: 02.247, 02.248, 03.008, 03.011, 03.012, 03.015, 03.016, 03.020, 
03.022, 03.024, 04.059, 04.067, 04.068, 04.069, 04.075, 04.079, 04.084, 08.127, 09.687 and 13.200] 
would be metabolised to innocuous products at the reported levels of intake as flavouring substances.  
It was noted that no repeated dose toxicity studies have been provided for any of the candidate 
substances and only a few studies were available on supporting substances. However, these 
toxicological data were consistent with the conclusions in the present Flavouring Group Evaluation 
using the Procedure. 
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It was concluded that on the basis of the default MSDI approach the 20 candidate substances would 
not give rise to safety concerns at estimated levels of intake arising from their use as flavouring 
substances.  
When the estimated intakes were based on the mTAMDI approach they were 3200 
micrograms/person/day for the two flavouring substances belonging to structural class I and for five of 
the seven flavouring substances belonging to structural class II. The mTAMDI for the two remaining 
flavouring substances from class II are 3500 and 14000 micrograms/person/day. These intakes are 
above the threshold of concern for structural class I of 1800 micrograms/person/day and for structural 
class II of 540 micrograms/person/day. For 10 candidate substances belonging to structural class III 
the mTAMDI are 860, 2500, 3200 or 3900 microgram/person/day, which are above the threshold of 
concern of 90 micrograms/person/day. For one substance from structural class III the mTAMDI of 58 
micrograms/person/day is below the threshold. This substance is also expected to be metabolised to 
innocuous products.  
Thus, for 19 of the 20 flavouring substances considered in this Opinion the intakes, estimated on the 
basis of the mTAMDI, exceed the relevant threshold for their structural class, to which the flavouring 
substances have been assigned. Therefore, for these 19 substances, more reliable exposure data are 
required. On the basis of such additional data, these flavouring substances should be reconsidered 
along the steps of the Procedure. Following this procedure additional toxicological data might become 
necessary. 
In order to determine whether the conclusion for the 20 candidate substances can be applied to the 
materials of commerce, it is necessary to consider the available specifications. Specifications including 
purity criteria and identity for the materials of commerce have been provided for all 20 flavouring 
substances. 
For all the 20 candidate substances [FL-no: 02.247, 02.248, 03.008, 03.011, 03.012, 03.015, 03.016, 
03.020, 03.022, 03.024, 04.059, 04.067, 04.068, 04.069, 04.075, 04.079, 04.084, 08.127, 09.687 and 
13.200] the Panel concluded that they would present no safety concern at the estimated levels of intake 
based on the MSDI approach. 
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TABLE 1: SPECIFICATION SUMMARY OF THE SUBSTANCES IN THE FLAVOURING GROUP EVALUATION 23, REVISION 3 
Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 23, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
02.247 
 
l-Menthoxyethanol 
O
OH
4154 
 
38618-23-4 
Liquid 
C12H24O2 
200.32 
Practically insoluble 
or insoluble 
Freely soluble 
100 
 
IR NMR MS 
99 % 
1.457-1.467 
0.930-0.950 
 
Register name to be changed 
to L-1-Menthoxyethanol. 
02.248 
 
Vanillin 3-(l-menthoxy)propane-1,2-diol 
acetal 
O
O
O
OHO
3904 
 
180964-47-0 
Solid 
C21H32O5 
364.49 
Very slightly soluble 
Freely Soluble 
 
78-80 
IR NMR 
97 % 
n.a. 
n.a. 
 
Mixture of four 
stereoisomers with equal 
ratios of the isomers (EFFA, 
2010a). 
03.008 
 
2-Acetoxy-1,8-cineole 
O
O
O
 
 
 
57709-95-2 
Solid 
C12H20O3 
212.29 
Practically insoluble 
or insoluble 
Freely soluble 
299 
89 
MS 
95 % 
n.a. 
n.a. 
 
Register name to be changed 
to (1R, 4S, 6S)-2-
Oxabicyclo[2.2.2]octan-6-
ol, 1,3,3-trimethyl-, 6-
acetate. 
03.011 
 
Benzyl methyl ether O
 
 
10910 
538-86-3 
Liquid 
C8H10O 
122.17 
Practically insoluble 
or insoluble 
Freely soluble 
169 
 
MS 
95 % 
1.498-1.504 
0.962-0.968 
 
 
03.012 
 
Benzyl octyl ether O
 
 
 
54852-64-1 
Liquid 
C15H24O 
220.35 
Practically insoluble 
or insoluble 
Freely soluble 
148 (12 hPa) 
 
MS 
95 % 
1.485-1.491 
0.903-0.909 
 
 
03.015 
 
Ethyl geranyl ether 
O  
 
 
40267-72-9 
Liquid 
C12H22O 
182.31 
Practically insoluble 
or insoluble 
Freely soluble 
218 
 
MS 
95 % 
1.463-1.469 
0.861-0.867 
 
 
03.016 
 
Hexyl methyl ether O  4291 
 
4747-07-3 
Liquid 
C7H16O 
116.20 
Practically insoluble 
or insoluble 
Freely soluble 
126 
 
MS 
95 % 
1.395-1.401 
0.766-0.772 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 23, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
03.020 
 
alpha-Terpinyl methyl ether 
O
 
 
 
14576-08-0 
Liquid 
C11H20O 
168.28 
Practically insoluble 
or insoluble 
Freely soluble 
216 
 
MS 
95 % 
1.461-1.467 
0.885-0.891 
 
Racemate. 
03.022 
 
1-Methoxy-1-decene O
 
4161 
 
79930-37-3 
Liquid 
C11H22O 
170 
Insoluble 
Soluble 
89 (12 hPa) 
 
IR NMR 
98 % 
1.430-1.438 
0.807-0.817 
 
Mixture of (E)- and (Z)-
isomers (EFFA, 2010a).  
> 40 % E isomer and > 40 % 
Z isomer (EFFA, 2011a).  
03.024 
 
Digeranyl ether 
O
4664 
 
31147-36-1 
Liquid 
C20H34O 
290.48 
Sparingly soluble 
Soluble 
130 (0.33 Torr) 
 
NMR MS 
>96% 
1.477-1.487 
0.867-0.876 
 
 
04.059 
 
Carvacryl methyl ether 
O
 
 
11224 
6379-73-3 
Liquid 
C11H16O 
164.25 
Very slightly soluble 
Freely soluble 
217 
 
MS 
95 % 
1.501-1.507 
0.937-0.943 
 
 
04.067 
 
1-Ethoxy-2-methoxybenzene O
O  
 
 
17600-72-5 
Liquid 
C9H12O2 
152.19 
Very slightly soluble 
Freely soluble 
213 
 
MS 
95 % 
1.518-1.524 
1.044-1.050 
 
 
04.068 
 
1-Ethoxy-4-methoxybenzene 
O
O
 
 
 
5076-72-2 
Solid 
C9H12O2 
152.19 
Practically insoluble 
or insoluble 
Freely soluble 
217 
37 
MS 
95 % 
n.a. 
n.a. 
 
 
04.069 
 
1-Ethyl-4-methoxybenzene O
 
 
 
1515-95-3 
Liquid 
C9H12O 
136.19 
Practically insoluble 
or insoluble 
Freely soluble 
195 
 
MS 
95 % 
1.504-1.510 
0.955-0.961 
 
 
04.075 
 
1-Methoxynaphthalene 
O
 
 
2216-69-5 
Liquid 
C11H10O 
158.20 
Practically insoluble 
or insoluble 
Freely soluble 
270 
6 
MS 
95 % 
1.622-1.628 
1.093-1.099 
 
 
04.079 
 
Methyl-4-methoxybenzyl ether O
O  
 
 
1515-81-7 
Liquid 
C9H12O2 
152.19 
Practically insoluble 
or insoluble 
Freely soluble 
225 
 
MS 
95 % 
1.508-1.514 
1.023-1.029 
 
Register name to be changed 
to Methyl 4-methoxybenzyl 
ether. 
04.084 
 
1,2,3-Trimethoxybenzene 
O O
O  
 
634-36-6 
Solid 
C9H12O3 
168.19 
Practically insoluble 
or insoluble 
Freely soluble 
235 
47 
MS 
95 % 
n.a. 
n.a. 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 23, Revision 3 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 
3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. 
Index 4) 
Spec.gravity 
5) 
Specification comments 
08.127 
 
2-(4-Methoxyphenoxy)propionic acid 
O
O
OH
O  
 
 
Solid 
C10H12O4 
196.20 
Slightly soluble 
Freely soluble 
377 
158 
NMR 
95 % 
n.a. 
n.a. 
 
Racemate (EFFA, 2010a). 
CASrn to be introduced in 
Register 158833-38-6. 
09.687 
 
2-Phenoxyethyl butyrate 
O
O
O  
 
23511-70-8 
Liquid 
C12H16O3 
208.26 
Practically insoluble 
or insoluble 
Freely soluble 
130 (5 hPa) 
 
MS 
95 % 
1.495-1.501 
1.057-1.063 
 
 
13.200 
 
5-Isopropyl-2,6-diethyl-2-methyltetrahydro-
2H-pyran 
O
 
4680 
 
1120363-98-5 
Liquid 
C13H26O 
198.35 
Insoluble 
Slightly soluble 
93 (10hPa) 
 
IR NMR MS 
95 % 
1.4450-
1.4470 
0.8620-
0.8640 
 
Approx. 61 % of 
(2R,5R,6R)-2,6-Diethyl-5-
isopropyl-2-
methyltetrahydropyran 
(DIMP) and (2S,5S,6S)-
DIMP;  
33 % of (2S,5R,6R)-DIMP 
and (2R,5S,6S)-DIMP; 4 % 
of (2R,5R6S)-DIMP and 
(2S,5S,6R)-DIMP; 1 % of 
(2S,5R,6S)-DIMP and 
(2R,5S,6R)-DIMP. 
 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 %  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
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TABLE 2A: SUMMARY OF SAFETY EVALUATION APPLYING THE PROCEDURE (BASED ON INTAKES CALCULATED BY THE MSDI APPROACH) 
Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
04.059 
 
Carvacryl methyl ether 
O
1.2 
 
Class I 
A3: Intake below threshold 
4) 6)  
04.084 
 
1,2,3-Trimethoxybenzene 
O O
O 0.012 
 
Class I 
A3: Intake below threshold 
4) 6)  
03.008 
 
2-Acetoxy-1,8-cineole 
O
O
O
0.037 
 
Class II 
A3: Intake below threshold 
4) 6)  
03.011 
 
Benzyl methyl ether O 1.9 
 
Class II 
A3: Intake below threshold 
4) 6)  
03.012 
 
Benzyl octyl ether O 0.24 
 
Class II 
A3: Intake below threshold 
4) 6)  
03.015 
 
Ethyl geranyl ether 
O
0.012 
 
Class II 
A3: Intake below threshold 
4) 6)  
03.016 
 
Hexyl methyl ether O  0.012 
 
Class II 
A3: Intake below threshold 
4) 6)  
03.024 
 
Digeranyl ether 
O
49 
 
Class II 
A3: Intake below threshold 
4) 6)  
04.079 
 
Methyl-4-methoxybenzyl ether O
O
0.61 
 
Class II 
A3: Intake below threshold 
4) 6)  
02.247 
 
l-Menthoxyethanol 
O
OH
15 
 
Class III 
A3: Intake below threshold 
4) 6)  
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Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation remarks 
02.248 
 
Vanillin 3-(l-menthoxy)propane-1,2-diol 
acetal 
O
O
O
OHO
0.61 
 
Class III 
A3: Intake below threshold 
4) 6)  
03.020 
 
alpha-Terpinyl methyl ether 
O
4.1 
 
Class III 
A3: Intake below threshold 
4) 6)  
03.022 
 
1-Methoxy-1-decene O 6.1 
 
Class III 
A3: Intake below threshold 
4) 6)  
04.067 
 
1-Ethoxy-2-methoxybenzene O
O
0.12 
 
Class III 
A3: Intake below threshold 
4) 6)  
04.068 
 
1-Ethoxy-4-methoxybenzene 
O
O 0.67 
 
Class III 
A3: Intake below threshold 
4) 6)  
04.069 
 
1-Ethyl-4-methoxybenzene O 0.073 
 
Class III 
A3: Intake below threshold 
4) 6)  
04.075 
 
1-Methoxynaphthalene 
O
0.061 
 
Class III 
A3: Intake below threshold 
4) 6)  
08.127 
 
2-(4-Methoxyphenoxy)propionic acid 
O
O
OH
O 0.011 
 
Class III 
A3: Intake below threshold 
4) 6)  
09.687 
 
2-Phenoxyethyl butyrate 
O
O
O 0.085 
 
Class III 
A3: Intake below threshold 
4) 6)  
13.200 
 
5-Isopropyl-2,6-diethyl-2-
methyltetrahydro-2H-pyran 
O
12 
 
Class III 
A3: Intake below threshold 
4) 6)  
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
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3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
6) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 1 (based on intake calculated by the MSDI approach). 
7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism. 
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
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TABLE 2B: EVALUATION STATUS OF HYDROLYSIS PRODUCTS OF CANDIDATE ESTERS  
Table 2b: Evaluation Status of Hydrolysis Products of Candidate Esters 
FL-no EU Register name 
JECFA no 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 
Procedure path (JECFA) 5) 
Comments 
 2-Hydroxy-1.8-cineole 
O
OH
Not evaluated as flavouring substance  Not in EU-Register 
 2-Phenoxyethanol 
O
OH
Not evaluated as flavouring substance  Not in EU-Register 
02.224 3-(1-Menthoxy)propane-1,2-diol 
1408 
O OH
OH
 
No safety concern a) 
 
 
Class I 
A3: Intake below threshold 
 
05.018 Vanillin 
889 
HO
O
O
 
 
No safety concern b) 
Category A c) 
 
Class I 
A3: Intake above threshold, A4: Not 
endogenous, A5: Adequate NOAEL exists 
 
08.002 Acetic acid 
81 O
OH  
Category 1 d) 
No safety concern e) 
Category A c) 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
 
08.005 Butyric acid 
87 
OH
O
 
Category 1 d) 
No safety concern e) 
Category A c) 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
 
1) Category 1: Considered safe in use   Category 2: Temporarily considered safe in use   Category 3: Insufficient data to provide assurance of safety in use   Category 4): Not acceptable due to evidence of toxicity. 
2) No safety concern at estimated levels of intake. 
3) Category A: Flavouring substance, which may be used in foodstuffs Category B: Flavouring substance which can be used provisionally in foodstuffs. 
4) Threshold of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
5) Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
a) (JECFA, 2005c). 
b) (JECFA, 2002b). 
c) (CoE, 1992). 
d) (SCF, 1995). 
e) (JECFA, 1999b). 
ND) Not detected. 
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TABLE 3: SUPPORTING SUBSTANCES SUMMARY 
Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
02.014 alpha-Terpineol 
HO
3045 
62 
98-55-5 
366 
JECFA specification (JECFA, 
1998b) 
2600  
No safety concern a) 
Category A b) 
 
03.001 1,8-Cineole 
O
2465 
182 
470-82-6 
1234 
JECFA specification (JECFA, 
2003b) 
1200  
No safety concern c) 
Category B b) 
 
03.003 Benzyl ethyl ether O
 
2144 
521 
539-30-0 
1252 
JECFA specification (JECFA, 
2003b) 
0.0024  
No safety concern c) 
Deleted b) 
 
03.005 2-Butyl ethyl ether O
 
3131 
10911 
2679-87-0 
1231 
JECFA specification (JECFA, 
2003b) 
6.9  
No safety concern c) 
 
 
03.006 2-Methoxyethyl benzene O
 
3198 
11812 
3558-60-9 
1254 
JECFA specification (JECFA, 
2003b) 
26  
No safety concern c) 
 
 
03.007 1,4-Cineole 
O
3658 
11225 
470-67-7 
1233 
JECFA specification (JECFA, 
2003b) 
3.9  
No safety concern c) 
 
 
03.010 Benzyl butyl ether O
 
2139 
520 
588-67-0 
1253 
JECFA specification (JECFA, 
2003b) 
0.012  
No safety concern c) 
Deleted b) 
 
03.019 Prenyl ethyl ether O
 
3777 
 
22094-00-4 
1232 
JECFA specification (JECFA, 
2003b) 
21  
No safety concern c) 
 
 
04.014 1-Methoxy-2-methylbenzene O 2680 
187 
578-58-5 
1242 
JECFA specification (JECFA, 
2003b) 
2.4  
No safety concern c) 
Deleted b) 
 
04.015 1-Methoxy-4-methylbenzene O
 
2681 
188 
104-93-8 
1243 
JECFA specification (JECFA, 
2003b) 
0.49  
No safety concern c) 
Category B b) 
 
04.016 1,3-Dimethoxybenzene OO
 
2385 
189 
151-10-0 
1249 
JECFA specification (JECFA, 
2003b) 
4.6  
No safety concern c) 
Category A b) 
 
04.032 Anisole O 2097 
2056 
1241 
JECFA specification (JECFA, 
0.024  
No safety concern c) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
100-66-3 2003b) Category B b) 
04.033 beta-Naphthyl ethyl ether O 2768 
2058 
93-18-5 
1258 
JECFA specification (JECFA, 
2003b) 
43  
No safety concern c) 
Category A b) 
 
04.034 1,4-Dimethoxybenzene O
O
2386 
2059 
150-78-7 
1250 
JECFA specification (JECFA, 
2003b) 
15  
No safety concern c) 
Category A b) 
 
04.038 Carvacryl ethyl ether 
O
2246 
11840 
4732-13-2 
1247 
JECFA specification (JECFA, 
2003b) 
0.085  
No safety concern c) 
 
 
04.039 1-Methoxy-4-propylbenzene O
 
2930 
11835 
104-45-0 
1244 
JECFA specification (JECFA, 
2003b) 
20  
No safety concern c) 
 
No ADI allocated 
(JECFA, 1981a). 
04.040 1,2-Dimethoxy-4-vinylbenzene O
O
3138 
11228 
6380-23-0 
1251 
JECFA specification (JECFA, 
2003b) 
0.012  
No safety concern c) 
 
 
04.043 1-Isopropyl-2-methoxy-4-
methylbenzene 
O
3436 
11245 
1076-56-8 
1246 
JECFA specification (JECFA, 
2003b) 
1.7  
No safety concern c) 
 
 
04.054 Isobutyl beta-naphthyl ether 
O
3719 
11886 
2173-57-1 
1259 
JECFA specification (JECFA, 
2003b) 
1.2  
No safety concern c) 
 
 
04.062 1,2-Dimethoxybenzene O
O
3799 
10320 
91-16-7 
1248 
JECFA specification (JECFA, 
2003b) 
1.6  
No safety concern c) 
 
 
04.063 1,3-Dimethyl-4-methoxybenzene 
O
3828 
 
6738-23-4 
1245 
JECFA specification (JECFA, 
2003b) 
0.12  
No safety concern c) 
 
 
04.074 2-Methoxynaphthalene O  
 
93-04-9 
1257 
JECFA specification (JECFA, 
2003b) 
3.5  
No safety concern c) 
 
 
08.049 Phenoxyacetic acid 
O
OH
O 2872 
2005 
122-59-8 
1026 
JECFA specification (JECFA, 
2002d) 
30  
No safety concern d) 
Deleted b) 
 
09.487 2-Phenoxyethyl isobutyrate 
O
O
O
2873 
2089 
103-60-6 
1028 
JECFA specification (JECFA, 
2002d) 
1.7  
No safety concern d) 
Deleted b) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
09.830 Terpineol acetate 
O
O
3047 
205 
8007-35-0 
368 
JECFA specification (JECFA, 
1998b) 
220  
No safety concern a) 
 
 
13.037 2-(2-Methylprop-1-enyl)-4-
methyltetrahydropyran 
O 3236 
2269 
16409-43-1 
1237 
JECFA specification (JECFA, 
2003b) 
3.8  
No safety concern c) 
Category B b) 
 
13.088 3,6-Dihydro-4-methyl-2-(2-
methylprop-1-en-1-yl)-2H-pyran 
O 3661 
 
1786-08-9 
1235 
JECFA specification (JECFA, 
2003b) 
0.85  
No safety concern c) 
 
 
13.094 2,6,6-Trimethyl-2-
vinyltetrahydropyran 
O 3735 
10976 
7392-19-0 
1236 
JECFA specification (JECFA, 
2003b) 
0.024  
No safety concern c) 
 
 
1) EU MSDI: Amount added to food as flavouring substance in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Category 1: Considered safe in use, Category 2: Temporarily considered safe in use, Category 3: Insufficient data to provide assurance of safety in use, Category 4: Not acceptable due to evidence of toxicity. 
3) No safety concern at estimated levels of intake. 
4) Category A: Flavouring substance, which may be used in foodstuffs, Category B: Flavouring substance which can be used provisionally in foodstuffs. 
a) (JECFA, 2000a). 
b) (CoE, 1992). 
c) (JECFA, 2004a). 
d) (JECFA, 2002c). 
ND) No intake data reported. 
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ANNEX I: PROCEDURE FOR THE SAFETY EVALUATION 
The approach for a safety evaluation of chemically defined flavouring substances as referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a), named the "Procedure", is shown in schematic 
form in Figure I.1. The Procedure is based on the Opinion of the Scientific Committee on Food expressed on 
2 December 1999 (SCF, 1999a), which is derived from the evaluation Procedure developed by the Joint 
FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th meetings (JECFA, 1995; JECFA, 
1996a; JECFA, 1997a; JECFA, 1999b). 
The Procedure is a stepwise approach that integrates information on intake from current uses, structure-
activity relationships, metabolism and, when needed, toxicity. One of the key elements in the Procedure is 
the subdivision of flavourings into three structural classes (I, II, III) for which thresholds of concern (human 
exposure thresholds) have been specified. Exposures below these thresholds are not considered to present a 
safety concern. 
Class I contains flavourings that have simple chemical structures and efficient modes of metabolism, which 
would suggest a low order of oral toxicity. Class II contains flavourings that have structural features that are 
less innocuous, but are not suggestive of toxicity. Class III comprises flavourings that have structural 
features that permit no strong initial presumption of safety, or may even suggest significant toxicity (Cramer 
et al., 1978). The thresholds of concern for these structural classes of 1800, 540 or 90 microgram/person/day, 
respectively, are derived from a large database containing data on subchronic and chronic animal studies 
(JECFA, 1996a). 
In Step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The further steps 
address the following questions: 
• can the flavourings be predicted to be metabolised to innocuous products8 (Step 2)?  
• do their exposures exceed the threshold of concern for the structural class (Step A3 and B3)? 
• are the flavourings or their metabolites endogenous9 (Step A4)?  
• does a NOAEL exist on the flavourings or on structurally related substances (Step A5 and B4)? 
In addition to the data provided for the flavouring substances to be evaluated (candidate substances), 
toxicological background information available for compounds structurally related to the candidate 
substances is considered (supporting substances), in order to assure that these data are consistent with the 
results obtained after application of the Procedure.  
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity. Therefore, 
the right is reserved to use alternative approaches if data on specific flavourings warranted such actions. 
 
                                                     
 
8 “Innocuous metabolic products”: Products that are known or readily predicted to be harmless to humans at the 
estimated intakes of the flavouring agent” (JECFA, 1997a). 
 
9 “Endogenous substances”: Intermediary metabolites normally present in human tissues and fluids, whether free or 
conjugated; hormones and other substances with biochemical or physiological regulatory functions are not included 
(JECFA, 1997a). 
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Decision tree structural class 
Can the substance be predicted to be metabolised to innocuous products?
Procedure for Safety Evaluation of Chemically Defined Flavouring Substances 
Do the conditions of use result in an intake greater than the 
threshold of concern for the structural class?
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Data must be available on the  
substance or closely related  
substances to perform a safety 
evaluation
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is  high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
  Substance would not be    
expected to be of safety concern
Is the substance or are its metabolites endogenous?
Additional data required 
Step 1. 
Step 2. 
Step A3. 
Step A4. 
Step A5. 
Step B3. 
Step B4.
 Yes No
 Yes 
 No 
No
No
Yes
No
Yes
Yes
Yes
 No
Figure I.1 Procedure for Safety Evaluation of Chemically Defined Flavouring Substances
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ANNEX II: USE LEVELS / MTAMDI 
II.1 Normal and Maximum Use Levels 
For each of the 18 Food categories (Table II.1.1) in which the candidate substances are used, Flavour 
Industry reports a “normal use level” and a “maximum use level” (EC, 2000a). According to the Industry the 
”normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th 
percentile of reported usages (EFFA, 2002i). The normal and maximum use levels in different food 
categories have been extrapolated from figures derived from 12 model flavouring substances (EFFA, 2004e). 
Table II.1.1 Food categories according to Commission Regulation (EC) No 1565/2000 (EC, 2000a) 
Food category Description 
01.0 Dairy products, excluding products of category 02.0 
02.0 Fats and oils, and fat emulsions (type water-in-oil) 
03.0 Edible ices, including sherbet and sorbet 
04.1 Processed fruit 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), and nuts & seeds 
05.0 Confectionery 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & legumes, excluding bakery 
07.0 Bakery wares 
08.0 Meat and meat products, including poultry and game 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  
10.0 Eggs and egg products 
11.0 Sweeteners, including honey 
12.0 Salts, spices, soups, sauces, salads, protein products, etc. 
13.0 Foodstuffs intended for particular nutritional uses 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts 
15.0 Ready-to-eat savouries 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed in categories 01.0 – 15.0 
 
The “normal and maximum use levels” are provided by Industry all 20 candidate substances in the present 
flavouring group (EFFA, 2003k; EFFA, 2004af; EFFA, 2004j; EFFA, 2007a; Flavour Industry, 2006a; 
Flavour Industry, 2008a; Flavour Industry, 2009g; Flavour Industry, 2010i; Flavour Industry, 2011b) (Table 
II.1.2). 
Table II.1.2. Normal and Maximum use levels (mg/kg) for candidate substances in FGE.23Rev 3 (EFFA, 2003k; 
EFFA, 2004af; EFFA, 2004j; EFFA, 2007a; Flavour Industry, 2006a; Flavour Industry, 2008a; Flavour Industry, 
2009g; Flavour Industry, 2010i; Flavour Industry, 2011b) 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.
0 
06.
0 
07.0 08.0 09.0 10.
0 
11.
0 
12.0 13.
0 
14.
1 
14.
2 
15.0 16.0 
02.24
7 
7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
02.24
8 
- 
- 
2 
5 
- 
- 
- 
- 
5 
10 
10 
20 
5 
20 
5 
20 
- 
- 
2 
10 
- 
- 
- 
- 
10 
20 
- 
- 
2 
10 
2 
10 
- 
- 
10 
20 
03.00
8 
3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
15 
75 
3 
15 
10 
50 
- 
- 
5 
25 
03.01
1 
3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
03.01
2 
3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
03.01
5 
3 
15 
2 
10 
3 
15 
3 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
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Table II.1.2. Normal and Maximum use levels (mg/kg) for candidate substances in FGE.23Rev 3 (EFFA, 2003k; 
EFFA, 2004af; EFFA, 2004j; EFFA, 2007a; Flavour Industry, 2006a; Flavour Industry, 2008a; Flavour Industry, 
2009g; Flavour Industry, 2010i; Flavour Industry, 2011b) 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.
0 
06.
0 
07.0 08.0 09.0 10.
0 
11.
0 
12.0 13.
0 
14.
1 
14.
2 
15.0 16.0 
03.01
6 
3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
03.02
0 
3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
03.02
2 
0,001
5 
0,012
5 
0,001
5 
0,012
5 
0,01
5 
0,12
5 
0,001
5 
0,012
5 
0,001
5 
0,012
5 
0,1
5 
1,2
5 
- 
- 
0,01
5 
0,12
5 
0,001
5 
0,012
5 
0,001
5 
0,012
5 
- 
- 
- 
- 
0,001
5 
0,012
5 
- 
- 
0,1
5 
1,2
5 
0,1
5 
1,2
5 
0,001
5 
0,012
5 
0,001
5 
0,012
5 
03.02
4 
- 
- 
- 
- 
50 
100 
- 
- 
- 
- 
70 
100 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
15 
30 
30 
60 
- 
- 
50 
100 
04.05
9 
3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
04.06
7 
3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
04.06
8 
3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
04.06
9 
3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
04.07
5 
3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
04.07
9 
3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
04.08
4 
3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
08.12
7 
3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
3 
15 
10 
50 
15 
75 
5 
25 
09.68
7 
7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
13.20
0 
0,5 
5 
0,5 
10 
0,1 
10 
0,5 
10 
0,5 
10 
1 
50 
5 
10 
1 
5 
- 
- 
- 
- 
0,5 
5 
1 
50 
1 
10 
- 
- 
0,1 
5 
0,5 
5 
- 
- 
- 
- 
The candidate substances [FL-no. 02.248 and 13.200] are also anticipated to be used in chewing gum, which 
is not covered by any of the food categories. Normal/maximum use levels for chewing gum are reported to 
be 10/20 mg/kg for [FL-no: 02.248] and 50/1000 mg/kg for [FL-no:13.200]. For chewing gum, the intake 
estimate is 2 g/day. It is anticipated that all of the flavouring substance is released from the chewing gum. In 
the calculation of the mTAMDI of these two candidate substances, use level figures in Table II.1.2 and the 
use level of chewing gum ((use level of chewing gum in mg/kg) x (2 g daily intake of chewing gum) = 
mg/person/day) are summed up to a total mTAMDI value of 2500 µg/person/day for [FL-no: 02.248] and 
860 µg/person/day for [FL-no: 13.200]. These values are presented in table II.2.3 and 6.1. 
II.2 mTAMDI Calculations 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values is 
based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may consume 
the amount of flavourable foods and beverages listed in Table II.2.1. These consumption estimates are then 
multiplied by the reported use levels in the different food categories and summed up.  
Table II.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed per 
person per day (SCF, 1995) 
Class of product category Intake estimate (g/day) 
Beverages (non-alcoholic) 324.0 
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Table II.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed per 
person per day (SCF, 1995) 
Class of product category Intake estimate (g/day) 
Foods 133.4 
Exception a: Candy, confectionery 27.0 
Exception b: Condiments, seasonings 20.0 
Exception c: Alcoholic beverages 20.0 
Exception d: Soups, savouries 20.0 
Exception e: Others, e.g. chewing gum e.g. 2.0 (chewing gum) 
 
The mTAMDI calculations are based on the normal use levels reported by Industry. The seven food 
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as outlined in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a) and reported by the Flavour Industry in the 
following way (see Table II.2.2): 
• Beverages (SCF, 1995) correspond to food category 14.1 (EC, 2000a) 
• Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13, and/or 16 
(EC, 2000a) 
• Exception a (SCF, 1995) corresponds to food category 5 and 11 (EC, 2000a) 
• Exception b (SCF, 1995) corresponds to food category 15 (EC, 2000a) 
• Exception c (SCF, 1995) corresponds to food category 14.2 (EC, 2000a) 
• Exception d (SCF, 1995) corresponds to food category 12 (EC, 2000a) 
• Exception e (SCF, 1995) corresponds to others, e.g. chewing gum. 
Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 (EC, 
2000a) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation (EC) No 1565/2000 Distribution of the seven SCF food categories 
Key Food category Food Beverages Exceptions 
01.0 Dairy products, excluding products of category 02.0 Food   
02.0 Fats and oils, and fat emulsions (type water-in-oil) Food   
03.0 Edible ices, including sherbet and sorbet Food   
04.1 Processed fruit Food   
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), 
and nuts & seeds 
Food   
05.0 Confectionery   Exception a 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & 
legumes, excluding bakery 
Food   
07.0 Bakery wares Food   
08.0 Meat and meat products, including poultry and game Food   
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  Food   
10.0 Eggs and egg products Food   
11.0 Sweeteners, including honey   Exception a 
12.0 Salts, spices, soups, sauces, salads, protein products, etc.    Exception d 
13.0 Foodstuffs intended for particular nutritional uses Food   
14.1 Non-alcoholic ("soft") beverages, excl. dairy products  Beverages  
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts   Exception c 
15.0 Ready-to-eat savouries   Exception b 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be 
placed in categories 01.0 - 15.0 
Food   
Flavouring Group Evaluation 23, Revision 3
 
 
35 EFSA Journal 2011; 9(10):2398 
 
The mTAMDI values (see Table II.2.3) are presented for each of 20 flavouring substances in the present 
flavouring group (EFFA, 2003k; EFFA, 2004af; EFFA, 2004j; EFFA, 2007a; Flavour Industry, 2006a; 
Flavour Industry, 2008a; Flavour Industry, 2009g; Flavour Industry, 2010i; Flavour Industry, 2011b). The 
mTAMDI values are only given for highest reported normal use levels (see Table II.2.3). 
TableII.2.3 Estimated intakes based on the mTAMDI approach 
FL-no EU Register name mTAMDI 
(μg/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
04.059 Carvacryl methyl ether 3200 Class I 1800 
04.084 1,2,3-Trimethoxybenzene 3200 Class I 1800 
03.008 2-Acetoxy-1,8-cineole 3500 Class II 540 
03.011 Benzyl methyl ether 3200 Class II 540 
03.012 Benzyl octyl ether 3200 Class II 540 
03.015 Ethyl geranyl ether 3200 Class II 540 
03.016 Hexyl methyl ether 3200 Class II 540 
03.024 Digeranyl ether 14000 Class II 540 
04.079 Methyl-4-methoxybenzyl ether 3200 Class II 540 
02.247 l-Menthoxyethanol 3900 Class III 90 
02.248 Vanillin 3-(l-menthoxy)propane-1,2-diol acetal 2500 Class III 90 
03.020 alpha-Terpinyl methyl ether 3200 Class III 90 
03.022 1-Methoxy-1-decene 58 Class III 90 
04.067 1-Ethoxy-2-methoxybenzene 3200 Class III 90 
04.068 1-Ethoxy-4-methoxybenzene 3200 Class III 90 
04.069 1-Ethyl-4-methoxybenzene 3200 Class III 90 
04.075 1-Methoxynaphthalene 3200 Class III 90 
08.127 2-(4-Methoxyphenoxy)propionic acid 3200 Class III 90 
09.687 2-Phenoxyethyl butyrate 3900 Class III 90 
13.200 5-Isopropyl-2,6-diethyl-2-methyltetrahydro-2H-pyran 860 Class III 90 
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ANNEX III: METABOLISM 
III.1. Introduction 
The candidate substances are examples of aliphatic, alicyclic or aromatic ethers. On the basis of their 
structure they can be divided into seven subgroups:  
1) aliphatic ethers [FL-no: 03.015, 03.016 and 03.022],  
2) alicyclic ethers [FL-no: 03.008 and 13.200],  
3) alicyclic hydrocarbons with an ether side chain [FL-no: 02.247, 02.248 and 03.020] of which [FL-no: 
02.248] has an acetal moiety,  
4) benzyl ethers [FL-no: 03.011 and 03.012],  
5) phenol ethers [FL-no: 04.059, 04.067, 04.068, 04.069, 04.079, 04.084, 08.127 and 09.687],  
6) naphthol ethers [FL-no: 04.075] and  
7) long chain aliphatic ethers [FL-no: 03.024] (see Table III.1). 
Table III.1. Subgroups. The supporting substances are listed in brackets. 
FL-no EU Register name Structural formula  
1 Aliphatic Ethers 
03.015 Ethyl geranyl ether 
O
 
03.016 Hexyl methyl ether O  
03.022 1-Methoxy-1-decene   O  
(03.005) (2-Butyl ethyl ether) O  
(03.006) (2-Methoxyethyl benzene) O  
(03.019) (Prenyl ethyl ether) O  
2 Alicyclic Ethers 
03.008 2-Acetoxy-1,8-cineole 
O
O
O
 
13.200 5-Isopropyl-2,6-diethyl-2-methyltetrahydro-2H-
pyran 
O
 
(03.001) (1,8-Cineole) 
O
 
(03.007) (1,4-Cineole) 
O
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Table III.1. Subgroups. The supporting substances are listed in brackets. 
FL-no EU Register name Structural formula  
(13.037) (2-(2-Methylprop-1-enyl)-4-methyltetrahydropyran) 
O
 
(13.088) (3,6-Dihydro-4-methyl-2-(2-methylprop-1-en-1-yl)-
2H-pyran) 
O  
(13.094) (2,6,6-Trimethyl-2-vinyltetrahydropyran) 
O
 
3 Alicyclic Hydrocarbons with Ether Side Chain 
02.247 l-Menthoxyethanol 
O
OH
 
02.248 Vanillin 3-(l-menthoxy)propane-1,2-diol acetal 
O
O
O
OHO
 
03.020 alpha-Terpinyl methyl ether  
O
 
(02.014) (alpha-Terpineol) 
HO
 
(09.830) (Terpineol acetate) 
O O
 
4 Benzyl Ethers 
03.011 Benzyl methyl ether O  
03.012 Benzyl octyl ether O  
(03.003) (Benzyl ethyl ether) O  
(03.010) (Benzyl butyl ether) 
O
 
5 Phenol Ethers 
04.059 Carvacryl methyl ether 
O
 
04.067 1-Ethoxy-2-methoxybenzene O
O
 
04.068 1-Ethoxy-4-methoxybenzene 
O
O  
04.069 1-Ethyl-4-methoxybenzene 
O
 
04.079 Methyl 4-methoxybenzyl ether O
O
 
04.084 1,2,3-Trimethoxybenzene 
O O
O  
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Table III.1. Subgroups. The supporting substances are listed in brackets. 
FL-no EU Register name Structural formula  
08.127 2-(4-Methoxyphenoxy)propionic acid O
O
OH
O
 
09.687 2-Phenoxyethyl butyrate 
O
O
O  
(04.014) (1-Methoxy-2-methylbenzene) O  
(04.015) (1-Methoxy-4-methylbenzene) 
O
 
(04.016) (1,3-Dimethoxybenzene) 
O
O  
(04.032) (Anisole) 
O
 
 
 
(04.034) (1,4-Dimethoxybenzene) 
OO
 
 
 
(04.038) (Carvacryl ethyl ether) 
O
 
(04.039) (1-Methoxy-4-propylbenzene) O  
(04.040) (1,2-Dimethoxy-4-vinylbenzene) 
O
O  
(04.043) (1-Isopropyl-2-methoxy-4-methylbenzene) 
O
 
(04.062) (1,2-Dimethoxybenzene) OO  
(04.063) (1,3-Dimethyl-4-methoxybenzene) 
O
 
(08.049) (Phenoxyacetic acid) 
O
OH
O  
(09.487) (2-Phenoxyethyl isobutyrate) 
O
O
O
 
6 Naphthol Ethers 
04.075 1-Methoxynaphthalene 
O
 
(04.033) (beta-Naphthyl ethyl ether) O  
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Table III.1. Subgroups. The supporting substances are listed in brackets. 
FL-no EU Register name Structural formula  
(04.054) (Isobutyl beta-naphthyl ether) 
O
 
(04.074) (2-Methoxynaphthalene) O  
7 Long Chain Aliphatic Ether 
03.024 Digeranyl ether 
O
 
 
No toxicokinetic studies were found on the candidate substances. Data on absorption, distribution and 
excretion are available for supporting substances and are described below. 
III.2. Absorption, Distribution and Elimination 
Subgroup 1: Aliphatic Ethers [FL-no: 03.015, 03.016 and 03.022] 
The aliphatic ethers are expected to be rapidly absorbed from the gastrointestinal tract and excreted. 
Data on absorption, metabolism and urinary excretion of the aliphatic ethers in animals are available for the 
structurally-related substance methyl tertiary-butyl ether (MTBE). MTBE is completely absorbed, 
metabolised and excreted following oral administration of 40 mg/kg bw to rats. MTBE was totally absorbed 
by the Gastrointestinal (GI) tract (as demonstrated by the identical Area Under the Curve (AUC) value 
calculated after oral and intravenous administration); the peak plasma concentration was reached within 15 
minutes. It was then rapidly eliminated from the blood, with a reported half-life of 30 minutes, by exhalation 
as such (> 60 % of the administered dose) and metabolism to tertiary-butyl alcohol, which is mainly excreted 
into the urine (blood half-life =1-2 hours). At a higher dose (400 mg/kg bw), metabolism was saturated and 
the proportion of renal [14C] excretion decreased relatively to the pulmonary route of elimination. At 48 
hours post exposure, almost all the administered radioactivity was eliminated at both doses. No tissue-
specific affinity or gender differences were described in the toxicokinetics and distribution of MTBE (Miller 
et al., 1997). 
Subgroup 2: Alicyclic Ethers [FL-no: 03.008 and 13.200] 
After the oral administration of 200 mg/kg bw 1,8-cineole [FL-no: 03.001] (synonym: eucalyptol) to rabbits, 
peak plasma concentration of the parent compound occurred within 30 minutes and reached a maximum 
plasma level of 840 μg/dl, while the plasma level of the principal unconjugated metabolite, (+)-2-endo-
hydroxy-1,8-cineole, peaked at 2400 μg/dl within one hour post exposure and then decreased slowly between 
two and six hours. Peak plasma levels (1250 μg/dl) of the major conjugated metabolite, the glucuronide of 
(+)-2-exo-hydroxy-1,8-cineole, occurred within 1.5 to 2 hours after dosing (Miyazawa et al., 1989).  
When 4, 20 or 40 μl of rosemary oil as a oil/water emulsion, containing 39 % 1,8-cineole (approximately 
equivalent to 52, 260, and 520 mg/kg bw of 1,8-cineole, respectively) were administered orally to mice, 
blood levels of the parent compound reached a peak level 5 minutes following the exposure. At 260 mg/kg 
bw, blood levels remained fairly constant over the following 90 minutes. At 520 mg/kg bw, the peak blood 
concentration dropped to 60 % of the maximum value and remained in that range for the following 80 
minutes (Kovar et al., 1987). These results indicate that at doses up to 200 mg/kg, 1,8-cineole is rapidly 
Flavouring Group Evaluation 23, Revision 3
 
 
40 EFSA Journal 2011; 9(10):2398 
absorbed into the blood, and eliminated by conjugation to polar metabolites. At higher doses, metabolism 
appears to be slower, due to saturation of the metabolic pathway.  
In humans, data are available for the inhalation route. In four healthy volunteers exposed for twenty minutes 
to air passing over 4 ml of 1,8-cineole via a closed breathing circuit, 1,8-cineole showed biphasic elimination 
from the blood. The peak blood concentration was reached within 15 minutes in all the subjects, attaining 
similar values (about 460 - 1100 ng/ml), indicating small interindividual differences in the absorption phase. 
The mean half-life for distribution was 6.7 minutes, whereas the half-life for elimination is 104.6 minutes. 
However, 1,8-cineole distribution seemed to be affected by the body composition of the volunteer (Jäger et 
al., 1996).  
Subgroup 3: Alicyclic Hydrocarbons with Ether Side Chain [FL-no: 02.247, 02.248 and 03.020] 
Terpenes are rapidly absorbed in the GI tract and due to their lipophilicity are extensively distributed in the 
body. Using radio-labelled citral (3,7-dimethyl-2,6-octadienal), it was shown that in rats, 14C is widely 
distributed within 72 hours and citral is probably metabolised through various pathways to common 
biological metabolites which are incorporated into tissues. This however, constitutes only a very small 
proportion of the dose administered. Following oral administration of citral in rats, 67 % of the 5 mg/kg bw 
dose was excreted within 24 hours, 45 % of this was excreted in the urine. Radio-labelled metabolites 
appeared within 2 hours of administration (Diliberto et al., 1988).  
Following administration of 5 mg/kg bw of citral in rats, 95 % was excreted within 24 hours. The majority of 
this dose (60 %) was excreted in the urine, 20 % was excreted in the lungs as 14CO2 and 17 % was excreted 
in the faeces. A very small proportion (0.5 %) of 14C found in the urine was found to be unchanged citral and 
1.5 % of the total 14C was retained in the liver. At higher levels (960 mg/kg bw), between 60 % and 70 % of 
the 14C was excreted within 24 hours. Again, this was mostly excreted in the urine (47 %). However, a lower 
level was excreted as 14CO2. Faecal excretion was much more delayed than at lower doses up to 36 hours 
after administration and the rate of faecal elimination increased between 36 and 96 hours following 
administration. 95 % of the total 14C was eliminated within 96 hours. The identities of the metabolites were 
not determined in this study, however, they were shown to be polar hexane-insoluble unsaturated compounds 
(Phillips et al., 1976). 
Subgroup 4: Benzyl Ethers [FL-no: 03.011 and 03.012] 
Aromatic ethers containing a benzene ring are thought to be absorbed, distributed and excreted in a similar 
way as alkylbenzenes.  
On administration of n-propylbenzene to chinchilla rabbits, approximately 60 - 70 % was excreted in the 
urine within 24 hours as conjugates of glucuronide and hippuric acid. Ethylphenylcarbinyl glucosiduronic 
acid was readily isolated from the urine of these rabbits (El Masry et al., 1956). In the same study, about 50 
% of the administered dose of butylbenzene was shown to be excreted as the glucuronides of methyl-2-
phenylethylcarbinol and phenylpropylcarbinol and around 20 % was excreted as phenaceturic acid. 
Approximately 4 % was excreted as hippuric acid. 
Following administration of 5 ml/kg bw of n-propylbenzene, the urinary sulphate ratio of inorganic/total 
sulphate was reduced considerably between 24 and 72 hours. The sulphate ratio returned to normal after 96 
hours. An increase in alkyl chain length was shown to be associated with an increase in the time taken for the 
sulphate ratio to return to normal, which indicates an increase in the time taken to eliminate the substance 
from the body (Gerarde and Ahlstrom, 1966). 
Alkylbenzenes appear to be metabolised to innocuous products and excreted as conjugates of glucuronides 
and as hippuric acid in the urine.  
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Subgroup 5: Phenol Ethers [FL-no: 04.059, 04.067, 04.068, 04.069, 04.079, 04.084, 08.127 and 09.687] 
When the supporting substance anisole [FL-no: 04.032] (500 mg/kg bw) was administered to rabbits via 
stomach tube, about 80 % of the dose was excreted in the urine within 24 hours, mainly as the products of p-
hydroxylation and the corresponding glucuronide and sulphate. The unchanged ethers were not detected in 
the urine and no smell of anisole was detected in the breath of the rabbits (Bray et al., 1953). 
The majority (up to about 70 %) of p-methylanisole administered via gavage to six rabbits was excreted in 
the urine within 24 hours, after oxidation to anisic acid and subsequent glucuronidation and as p-cresol (the 
latter metabolite accounting for about 27 % of the administered dose) (Bray et al., 1955).  
When a single dose of [14C]-p-propylanisole (labelled at the methoxy position) was administered to female 
Wistar albino rats via oral intubation and to male CD-1 mice via the intraperitoneal route at dose levels of 
0.05, 0.5, 5, 50, 500 or 1500 mg/kg bw, at the lowest dose level the majority of radioactivity was excreted as 
14CO2 in the expired air (81.6 and 74.5 % in rats and mice, respectively), whereas the urinary excretion 
accounted for 8.0 and 15.0 % in rats and mice, respectively. As dose levels increased up to 1500 mg/kg bw, 
approximately equal amounts were excreted in the urine (37.1 and 38.0 % in rats and mice, respectively) and 
in the expired air as 14CO2 (47.2 and 49.9 % in rats and mice, respectively) within 72 hours, suggesting that 
the O-demethylation pathway becomes saturated at the higher dose levels. Approximately 1 - 5 % was 
excreted in the faeces regardless of the administered dose. However, in all the experimental conditions 
tested, more than 80 % of the administered dose was excreted within 72 hours after the treatment (Sangster et 
al., 1983).  
Approximately 67 % of a 100 μg dose of [14C]-methoxy-labelled p-propylanisole administered by gelatin 
capsule to two humans was recovered within 8 hours, the majority of which (43 %) in the expired air and the 
remainder (about 24 %) in the urine (Sangster et al., 1987).  
Subgroup 6: Naphthol Ethers [FL-no: 04.075] 
After absorption, the supporting substance beta-naphthyl methyl ether [FL-no: 04.033] is hydroxylated and 
excreted as a glucuronide (Williams, 1959a). 
Subgroup 7: Long Chain Aliphatic Ether [FL-no: 03.024] 
No data are available on the absorption, distribution and excretion of the substance in this sub-group or any 
supporting substances but as with the other substances in this flavouring group, digeranyl ether [FL-no: 
03.024] would be expected to be rapidly absorbed from the gastrointestinal tract and excreted as polar 
metabolites in the urine and in the exhaled air as CO2 in a similar way to the aliphatic saturated tertiary 
alcohols found in FGE.18, Revision 1 (EFSA, 2009a) and the non-polar hydrocarbons found in FGE.25 
(EFSA, 2008ba). 
III.3. Metabolism 
No metabolism studies were found for the candidate substances. 
Several metabolic options are available to aliphatic and aromatic ethers. One pathway for aliphatic and 
aromatic ethers is O-dealkylation to form the corresponding aldehydes and alcohols if a suitable alkyl 
substituent (methyl or ethyl) is attached to the ether oxygen. The resulting alcohols may be further oxidised 
followed by conjugation and excretion, while the aldehydes (i.e. acetaldehyde and formaldehyde) are 
oxidised to carboxylic acids, which participate in fundamental biochemical pathways, including the fatty acid 
pathway and tricarboxylic acid cycle, resulting in CO2 expiration. Alternatively, the aliphatic acyclic or 
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aromatic moiety may undergo cytochrome P450-catalysed C-oxidation (ring-hydroxylation or side-chain 
oxidation), followed by conjugation with sulphate or glucuronic acid and then excretion, mainly via the 
urinary route. 
Subgroup 1: Aliphatic Ethers [FL-no: 03.015, 03.016 and 03.022] 
Aliphatic ethers included in the present evaluation are expected to undergo NADPH-dependent P450-
catalysed O-dealkylation to the corresponding alcohols and aldehydes.  
In vitro, by using liver microsomes from Sprague-Dawley rats, methyl tertiary-butyl ether (MTBE) was O-
demethylated to form almost equal amounts of t-butyl alcohol (TBA) and formaldehyde (Brady et al., 1990). 
MTBE metabolism was inhibited 35 % by monoclonal antibodies to CYP2E1 and increased in acetone-
induced microsomes, indicating that MTBE is partially metabolised by this P450 isozyme. Pretreatment of 
rats via intraperitoneal injection with 1 or 5 ml MTBE/kg bw did not affect the activity of CYP2E1, but 
induced CYP2B1, suggesting that this CYP may be also involved in MTBE biotransformation (Brady et al., 
1990).  
In vivo, oral administration of 40 mg/kg bw of MTBE to rats resulted in the rapid production of TBA. The 
alcohol was detected in the blood (half life = 1-2 hours) and in the urine. At a 10-fold higher dose, the 
metabolism appeared to be saturated, and a higher percentage of the administered dose was recovered as 
parental compound in the exhaled air (Miller et al., 1997). 
In other studies methyl tertiary-butyl ether (MTBE) and ethyl tertiary-butyl ether were administered to rat by 
inhalation, while TBA, the major initial metabolite of the two ethers, was studied after oral gavage (250 
mg/kg bw). Only minor amounts of TBA and its conjugate were detected in the urine of rats dosed with the 
ethers, whereas 2-methyl-1,2-propanediol, 2-hydroxyisobutyrate and an unidentified TBA conjugate were 
the major urinary metabolites. The same major metabolites were found in TBA-treated rats, being unchanged 
TBA, its glucuronide and acetone only detected in minor amounts. Similar results were obtained in one 
human volunteer, taking 5 mg/kg TBA orally, suggesting that TBA, formed by MTBE and ETBE, is 
extensively metabolised by further oxidation reactions (Bernauer et al., 1998). 
It has been reported that diethyl ether was biodegraded to 14CO2 in amounts of 1 to 5 % in rats (Krantz and 
Carr, 1969), due to its O-demethylation to ethanol and acetaldehyde, followed by oxidation to acetate, which 
eventually enters the citric acid cycle. This further supports the likelyhood that the candidate aliphatic ethers 
may undergo O-dealkylation to form their corresponding alcohols and aldehydes, which are expected to 
subsequently participate in the fatty acid pathway and tricarboxylic acid cycle. 
The anticipated demethylated product of 1-methoxy-1-decene [FL-no: 03.022] is an enol, which will 
rearrange to the aldehyde, which subsequently can be oxidised to the carboxylic acid. 
Subgroup 2: Alicyclic Ethers [FL-no: 03.008 and 13.200]  
In humans and other animals, alicyclic ethers, such as the supporting substances 1,4-cineole [FL-no: 03.007] 
and 1,8-cineole [FL-no: 03.001], have been shown to be oxidised via P450 isoenzymes to yield polar 
hydroxylated metabolites, which are conjugated and excreted or further oxidised and excreted. Cleavage of 
the ether is, at most, a very minor metabolic pathway (Hiroi et al., 1995; Miyazawa et al., 2001a; Miyazawa 
et al., 2001b; Miyazawa and Shindo, 2001). 
The metabolism of 1,8-cineole [FL-no: 03.001] has been studied in various animal species. It has been 
reported that 1,8-cineole principally undergoes ring-hydroxylation to form 2- or 3-hydroxy-1,8-cineole, 
which are subsequently excreted as the glucuronic acid conjugates (Williams, 1959a) (see Figure III.1). 
Indeed, following the gavage administration of 800 mg 1,8-cineole/kg bw to male albino rats, major 
metabolites included 2- and 3-hydroxy-1,8-cineole and their conjugates and 1,8-dihydroxy-10-carboxy-p-
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menthane, which were hypothesised to be formed by the oxidation of the metabolite p-menthane-1,8-diol 
formed by cleavage of the ether linkage (Madyastha and Chadha, 1986).  
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Figure III.1  Metabolism of 1,8-cineole (eucalyptol) in rats and humans. 
These results are consistent with a more recent study, in which 1,8-cineole [FL-no: 03.001] metabolism in 
microsomes from male Hooded Wistar rats and humans was studied (Pass et al., 2001). To determine the 
effect on the efficiency of biotransformation, expressed as the intrinsic clearance (Vmax/Km) of the reaction, 
caused by possible induction of metabolism, rats were pre-treated daily for six days with a mixture of 
terpenes (255 mg 1,8-cineole/kg bw; 4 mg p-cymene/kg bw; 34 mg limonene/kg bw; 103 mg α-pinene/kg 
bw) by gavage, or 80 mg/kg bw of phenobarbital (PB). Liver microsomes prepared from pre-treated and 
control rats, as well human liver microsomes pooled from seven male patients were incubated with 5 – 200 
μM 1,8-cineole. Intrinsic clearance values were as follows: 27.5; 258.2; 1824.7 and 11.6 μl⋅mg protein-
1⋅minute-1 in microsomes from control, terpene-treated, PB-treated rats and humans, respectively. The 
efficiency in 1,8-cineole metabolism was similar in control rat and human microsomes, whereas terpenes 
and, at a higher extent, PB-induced rat microsomes metabolised 1,8-cineole more efficiently. This result 
suggests that terpenes are able to induce their own metabolism, in which CYP2B1 (induced by PB) is very 
likely involved (Pass et al., 2001). Although with differences in their relative amounts, qualitatively the 
various liver microsomes produced the same hydroxylated metabolites. Control rat microsomes produced 3-
hydroxy-1,8-cineole as the major metabolite, followed by 2- and 9-hydroxycineole. Microsomes from 
terpene-treated rats produced similar amounts of 2- and 3-hydroxy-1,8-cineole and lesser amounts of 9-
hydroxy-1,8-cineole. Of the six metabolites detected in the microsomes from PB-treated rats, 2-hydroxy-1,8-
cineole was the major metabolite, followed by 3- and 9-hydroxy-1,8-cineole, whereas the remaining three 
metabolites consisted of trace amounts of 7-hydroxy-1,8-cineole, 9-cineolic acid and one unknown 
hydroxycineole metabolite. 2-Hydroxy-1,8-cineole was the major metabolite from pooled human liver 
microsomes, while 9-hydroxy-1,8-cineole was the minor metabolite. The authors concluded that in rats and 
humans, oxidation was preferred at the aliphatic ring carbons over methyl substituents (Pass et al., 2001).  
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The metabolism of 1,8-cineole [FL-no: 03.001] was studied in vivo in rabbits treated by gavage with 200 
mg/kg bw. The major metabolites were identified as 2- and 3-hydroxy-1,8-cineole (Miyazawa et al., 1989). 
When rat and human liver microsomes and recombinant human CYPs (i.e. c-DNA expressed in insect cells) 
were incubated in vitro with 1,8-cineole, it was oxidised at high rates to 2-exo-hydroxy-1,8-cineole (see 
Figure III.1) (Miyazawa et al., 2001b; Miyazawa and Shindo, 2001). As indicated by results obtained with 
recombinant CYPs, P450 inducers (PB and pregnenolone 16-alpha-carbonitrile), and specific P450 
inhibitors, the reaction in humans is mainly catalysed by CYP3A2 and 3A4 in rat and human liver 
microsomes, respectively (Miyazawa et al., 2001a; Miyazawa et al., 2001b). Earlier studies also indicate that 
CYP3A family is induced by 1,8-cineole. Hepatic microsomes prepared from male Sprague-Dawley rats 
intraperitoneally injected 300 mg 1,8-cineole/kg bw once a day for five days showed increased levels of 2B1 
and 3A2 expression and in their related enzymatic activities (Hiroi et al., 1995). 
Hepatic microsomes from beta-naphthoflavone- or PB-pretreated female Wistar rats were used to investigate 
the inhibitory effects of 1,8-cineole [FL-no: 03.001] on the marker activities of CYP1A1 (ethoxyresorufin-O-
deethylase, EROD), 1A2 (methoxyresorufin-O-demethylase, MROD), and 2B1 (pentoxyresorufin-O-
depenylase, PROD). 1,8-Cineole caused no or negligible inhibition on EROD and MROD (up to 150 μM), 
while CYP2B1 activity was decreased in the presence of 1,8-cineole. The competion with the specific probe 
substrate for CYP2B1 indicates that also this isoform is involved in 1,8-cineole metabolism in the rat (De-
Oliveira et al., 1999). 
Oxidation of 1,4-cineole [FL-no: 03.007] was studied in rat and human liver microsomes as well as with 
recombinant human CYPs; in all cases the major identified metabolite was 2-exo-hydroxy-1,4-cineole. 
Based on the results obtained with single recombinant isoforms on the effects of specific CYP inhibitors and 
antibodies and on the data from correlation studies, CYP3A4 was identified as the CYP, mainly responsible 
for 1,4-cineole oxidation. Similarly, CYP3A2 was active in the rat (Miyazawa et al., 2001a). 
In rabbits, 1,4-cineole [FL-no: 03.007] is metabolised by ring- and side-chain hydroxylation. Urinary 
metabolites collected over three days following administration of 10,000 mg 1,4-cineole/rabbit include the 
ring-hydroxylation product 3,8-dihydroxy-1,4-cineole, the side-chain hydroxylation product 9-hydroxy-1,4-
cineole and its corresponding carboxylic acid, 1,4-cineole-9-carboxylic acid. Other metabolites included 8,9-
dihydroxy-1,4-cineole and 1,4-cineole-8-en-9-ol. No evidence of ether cleavage was observed at this dose 
level (Asakawa et al., 1988). 
Subgroup 3: Cyclic Hydrocarbons with Ether Side Chain [FL-no: 02.247, 02.248 and 03.020] 
The available data on alpha-terpineol [FL-no: 02.014] as supporting substance for subgroup 3, suggest that 
the candidate substance [FL-no: 03.020] would be metabolised by P450 isoenzymes to yield polar 
hydroxylated metabolites, which are conjugated to form glucuronic acid conjugates and excreted or are 
further oxidised and excreted. Cleavage of the ether is a minor metabolic pathway (JECFA, 1999a). The 
JECFA considered the metabolism of alpha-terpineol at their 51st meeting and they concluded that in humans 
and animals, terpenoid tertiary alcohols, of which alpha-terpineol is one, are conjugated primarily with 
glucuronic acid and are excreted in the urine and faeces. Unsaturated terpenoid alcohols may undergo allylic 
oxidation to form polar diol metabolites, which may be excreted either free or conjugated (Williams, 1959a; 
Parke et al., 1974a; Parke et al., 1974b; Horning et al., 1976; Ventura et al., 1985). 
Male albino rats were administered orally alpha-terpineol [FL-no: 02.014] (600 mg/kg bw), once daily for 20 
days as a suspension (in 1 % methyl cellulose solution, 2 ml as final volume). The urinary metabolites were 
qualitatively identified. A significant amount of the test item was excreted unmetabolised, and the allylic 
methyl oxidation was the major route of biotransformation. The reduction of the endocyclic double-bond 
was also seen. In addition, the treatment resulted in a substantial induction of P450-related activities in the 
liver (Madyastha and Srivatsan, 1988b). 
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Citral was shown to undergo first pass liver metabolism and also be metabolised by intestinal bacteria. 
Excretion of metabolites via the bile into the intestine, results in enterohepatic recirculation of citral-derived 
radioactivity (Diliberto et al., 1988). 
Citral has been shown to be metabolised to 7-carboxy-3-methylocta-2,6-dienoic acid and 7-carboxy-3-
methylocta-6-enoic acid (Williams, 1959a). These are considered to be innocuous products. 
At low pH similar to that found in the stomach, vanillin 3-l-menthoxypropane-1,2-diol acetal [FL-no: 
02.248] is readily hydrolysed. In a hydrolysis study, 12 - 39 mM vanillin 3-l-menthoxypropane-1,2-diol 
acetal underwent 91 % hydrolysis at pH 2 within 45 minutes. At pH 3, approximately 86 % of vanillin 3-l-
menthoxypropane-1,2-diol acetal hydrolysed within 90 minutes. At a pH of 4, approximately 92 % of the 
acetal hydrolysed within 8 hours. At a pH of 5, approximately 12 % of the flavouring agent hydrolysed 
within 8 hours (Reitz, 1995). 
Under acidic conditions, pH 2.6, vanillin propylene glycol acetal began to hydrolyse immediately with 
approximately 3 % of the acetal disappearing and 92 % hydrolysed within two hours. At a pH of 1.8, 
approximately 90 % of vanillin propylene glycol acetal hydrolysed immediately and 93 % hydrolysed within 
five minutes (Bennett, 1997).  
As shown above vanillin 3-(l-menthoxy)propane-1,2-diol acetal [FL-no: 02.248] is shown to be hydrolysed 
to the corresponding ether and vanillin. It is expected that the alcohol groups in this ether subsequently are 
oxidised and that the carboxylic acid(s) are then excreted as such or after conjugation.  
Similarly, l-menthoxy-ethanol [FL-no: 02.247] is anticipated to be oxidised to the corresponding carboxylic 
acid and excreted. 
Subgroup 4: Aromatic Ethers Containing a Benzene Ring [FL-no: 03.011 and 03.012]  
No data are available on the candidate substances, however, alkylbenzenes are considered to be metabolised 
in a similar way to benzyl ethers. Male albino rats were dosed with quantities of n-propylbenzene and other 
alkylbenzenes at doses of up to 5 ml/kg. After dosing the animals were kept in metabolism cages and urine 
was collected in 24 hours fractions for 96 hours. Urine samples were analysed for organic and inorganic 
sulphates. The change in urinary sulphate ratio, inorganic/total was used to ascertain whether ring-
hydroxylation had occurred after administration of increasing doses of alkylbenzenes. Following dosing with 
n-propylbenzene, it was shown that at 48 hours the peak level of excretion is reached and all of the n-
propylbenzene is excreted by 96 hours following dosing at 5 ml/kg bw. The authors conclude that 
alkylbenzenes with shorter side chains are primarily exhaled as unchanged hydrocarbon. As the side chain 
increases in size, the proportion of alkylbenzene that is ring-hydroxylated and excreted in the urine also 
increases. Organic sulphate in the urine indicates that ring-hydroxylation is occuring in the body to form 
phenol derivatives. The longer the alkyl side-chain, the greater the level of organic sulphate in the urine and 
therefore the greater the level of ring-hydroxylation and production of phenol derivatives (Gerarde and 
Ahlstrom, 1966). 
Following administration of n-propylbenzene, it was observed that the main product in the urine was 
ethylphenylcarbinyl glucosiduronic acid. This shows that the major route of metabolism is via 
ethylphenylcarbinol, which is then conjugated with glucuronic acid. Another route is via 
benzylmethylcarbinol, which is more readily converted to hippuric acid. Another possible route is via 
omega-oxidation to beta-phenylproprionic acid, which can be subsequently beta-oxidised to benzoic acid (El 
Masry et al., 1956). 
Subgroup 5: Aromatic Ethers Containing a Phenol Ring [FL-no: 04.059, 04.067, 04.068, 04.069, 04.079, 
04.084, 08.127 and 09.687] 
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The supporting aromatic ethers are metabolised by ring-hydroxylation, cleavage of the methyl ether (O-
demethylation), and/or oxidation of the ring substituents.  
Several studies have demonstrated that anisole [FL-no: 04.032] principally undergoes P450-catalysed ring-
hydroxylation preferentially at the p-position, with O-demethylation and o-hydroxylation as the minor 
pathways (Daly and Jerina, 1969; Daly, 1970; Ohi et al., 1992; Takahara et al., 1986).  
Fifteen minutes in vitro incubation of 25 - 50 μmoles of 2-2H-anisole with 3-methylcholanthrene (3MC)-
induced liver microsomes resulted in o- and p-hydroxylation to form 2- and 4-hydroxyanisole, respectively 
(Daly and Jerina, 1969). In a similar study, 50 μmoles anisole [FL-no: 04.032] incubated for 15 minutes with 
liver homogenates from 3MC-pretreated rats, gave rise to 4 μmoles p-hydroxyanisole, 0.8 μmoles o-
hydroxyanisole and 0.2 μmoles phenol. Thus, in hepatic 3MC induced rat microsomes, p-hydroxylation is 
the major metabolic pathway of anisole biotrasformation, while O-demethylation and o-hydroxylation are the 
minor ones (Daly, 1970). In the same study, it is reported that ortho-substituents, including methyl groups, 
greatly reduced the O-demethylation but had little effects on para-hydroxylation. The presence of a methyl 
group in meta position had little effects on ortho- and para-hydroxylation of anisole. Para-substitution in the 
anisole molecule blocked para-hydroxylation of the ring and markedly stimulate O-demethylation and to a 
lesser extent meta-hydroxylation (Daly, 1970). These features are related to 3MC-induced rat microsomes, 
since in hepatic microsomes from control rat and rabbit, para-hydroxylation and O-demethylation are almost 
equally efficient (Daly, 1970).  
The effect of oxygen concentration on the metabolism of anisole [FL-no: 04.032] was investigated in a more 
recent study (Takahara et al., 1986). When phenobarbital-induced rat liver microsomes were incubated with 
2 mM anisole, in normoxic conditions, comparable levels of phenol (the product of O-demethylation) and the 
aromatic hydroxylated products, p-hydroxyanisole and o-hydroxyanisole were detected in 10 minutes’ 
incubations; no m-hydroxylation took place. In hypoxic conditions the levels of the 3 metabolites were 
markedly decreased. When anisole was incubated for 1 hour at different oxygen concentrations (24, 34, 54, 
74, 113 or 223 μM), the formation rates and the relative amounts of metabolites were dependent on the 
oxygen concentration, as the amount of O-demethylated product started decreasing at oxygen concentrations 
below 60 μM (typical oxygen pressure in the liver was 35 μM) (Takahara et al., 1986). Results were 
confirmed in a second study using the same protocol, in which also iso-propoxybenzene metabolism was 
investigated. Although the dependence on pO2 slightly differs with the two compounds, in both case the 
main metabolites were due to p-hydroxylation and O-demethylation with lower formation of the o-
hydroxylation product. No m- or side chain hydroxylation products were detected (Ohi et al., 1992). 
In vivo experiments on anisole [FL-no: 04.032] confirm that ring-hydroxylation predominates over O-
demethylation. Urine collected 24 hours post-administration of 0.5 g/kg bw of anisole via gavage to rabbits 
revealed that 2 % of the dose was unconjugated p-methoxyphenol (major) and, to a lower extent o- 
methoxyphenol, 48 % was conjugated with glucuronic acid, and 29 % was conjugated with sulphate. No 
evidence of ether cleavage was detected (Bray et al., 1953). The limited ether cleavage in the rabbit was 
confirmed by a study with rabbit liver microsomes incubated with 2 μmoles anisole for one hour (Axelrod, 
1956).  
p-Methylanisole [FL-no: 04.015] administered at 700 mg/rabbit to six rabbits via gavage undergoes mainly 
methyl group oxidation to yield anisic acid (p-methoxybenzoic acid), excreted as the glucuronic acid 
conjugate in the urine. A smaller amount (27 %) of p-methylanisole is demethylated and excreted in the 
urine as the sulphate or glucuronic acid conjugate of p-cresol. In humans and dogs, anisic acid (p-
methoxybenzoic acid) is excreted as conjugates of glucuronic acid and glycine (Bray et al., 1955). 
The majority of [14C]-p-propylanisole labelled at the methoxy position is metabolised via O-demethylation, 
resulting in the expiration of 14CO2, α- and ω-1 oxidation of the side-chain, leading to 1’- and 2’-hydroxy-p-
propylanisole, excreted in the urine and side-chain degradation yielding p-methoxyhippuric acid found in the 
urine conjugated with glycine (see Figure III.2). Radiolabeled p-propylanisole was administered to groups of 
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female Wistar albino rats via oral intubation and to male CD-1 mice via the intraperitoneal route at dose 
levels of 0.05, 0.5, 5, 50, 500 or 1500 mg/kg bw for both species. The excretion pathway greatly varied with 
dose. At the lowest dose level (0.05 mg/kg bw/day), the majority of the radioactivity is excreted as 14CO2 in 
expired air (81.6 and 74.5 % in rats and mice, respectively) compared to urinary excretion (8.0 and 15.0 % in 
rats and mice, respectively) within 72 hours. At the low dose levels, the major urinary metabolites were p-
methoxyhippuric acid and 2’-hydroxy-p-propylanisole. As dose levels increased, a metabolic shift to α- and 
ω-1 hydroxylation occurred, yielding greater amounts of the glucuronic acid urinary conjugates of 1’- and 
2’-hydroxy-p-propylanisole and the side-chain degradation product, p-methoxybenzoic acid conjugated with 
glycine. At the highest dose levels (500 or 1500 mg/kg bw) 1’- and 2’-hydroxy-p-propylanisole were present 
in the urine also as unconjugated products. Based on this study and other available studies in literature on 
structurally related substances such as trans-anethole (p-propenylanisole) and estragole, the plausible 
metabolic routes of p-propylanisole in rats and mice are presented in Figure III.2 (Sangster et al., 1983). 
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p-(1',2'-Dihydroxypropyl)anisole p-Methoxybenzoic acid
p-Methoxyhippuric acid  
Figure III.2  Metabolism of p-propylanisole in rats and humans. 
At low doses, the O-demethylation pathway for the metabolism of p-propylanisole predominates in humans 
as well. In a study in humans, two male volunteers were administered a gelatin capsule containing 100 μg 
[14C]-p-propylanisole (1.5 μg/kg bw). The majority (42.7 %) of the radioactivity was accounted for as 
exhaled 14CO2 within 48 hours, demonstrating that O-demethylation was the principal metabolic pathway for 
p-propylanisole. Comparison with results obtained with anethole and estragole, clearly indicates that p-
propylanisole, which has a saturated side-chain, is more efficiently and extensively O-demethylated than its 
two unsaturated congeners. The principal metabolic products identified in the urine included the glycine 
conjugate of 4-methyoxybenzoic acid and the glucuronides of 1- and 2-hydroxy-p-propylanisoles and 1,2-
dihydroxy-p-propylanisoles (Sangster et al., 1987). 
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p-Dimethoxybenzene [FL-no: 04.034] administered via gavage at 700 mg/kg bw to rabbits undergoes 
extensive O-demethylation to p-methoxyphenol (34 %) followed by excretion as a glucuronic acid or 
sulphate conjugate. Trace amounts of hydroquinone were reported. O-Demethylation of p-dimethoxybenzene 
was also reported to occur in vitro with rabbit liver slices (Bray et al., 1955). 
2-(4-Methoxyphenoxy)propionic acid [FL-no: 08.127] is expected to be excreted as such or after 
conjugation. 
Subgroup 6: Naphthol Ethers [FL-no: 04.075] 
No metabolism studies were found for the candidate substance, but data are available on the supporting 
substance 2-methoxynaphthalene. 2-Methoxynaphthalene is excreted as a glucuronic acid conjugate with the 
methyl ether linkage intact. The exact position of the glucuronic acid residue on the naphthyl moiety was not 
identified (Williams, 1959a). 
Subgroup 7: Long Chain Aliphatic Ethers [FL-no: 03.024] 
Whilst no metabolism data have been found for the candidate substance in subgroup 7, digeranyl ether [FL-
no: 03.024], data are available on substances that are supporting for the metabolism of longer chain ethers. 
Tsuji et al., concluded that dealkylation of ethers becomes less likely as the chain length increases and that 
ω-oxidation is more likely to occur (Tsuji et al., 1978). 
Male IISc rats were given [1-3H] geraniol in daily doses of 800 mg/kg bw by gavage for 20 consecutive 
days. Five urinary metabolites were identified via two primary pathways. In one pathway, the alcohol is 
oxidised to yield geranic acid (3,7-dimethyl-2,6-octadienoic acid) which is subsequently hydrated to yield 
3,7-dimethyl-3-hydroxy-6-octenoic acid (3-hydroxy citronellic acid). In a second pathway, the alcohol 
undergoes selective ω-oxidation of the C8-methyl to yield 8-hydroxygeraniol and 8-carboxygeraniol, the 
latter of which undergoes further oxidation to the principal urinary metabolite 2,6-dimethyl-2,6-
octadienedioic acid. It was demonstrated that administration of geraniol at a dose of 600 mg/kg bw by 
gavage for 1, 3 or 6 days induced expression of rat liver microsomal cytochrome P450 and geraniol 
hydroxylation, but not the activities of rat liver microsomal cytochrome b5, NADPH-cytochrome c 
reductase, and NADH-cytochrome c reductase, nor the activities of these enzymes in rat lung microsomes. 
Rabbits are also capable of ω-oxidation of geraniol, as both the Hildebrandt acid and its dihydro form (2,6-
dimethyl-2-octendioic acid; reduced or dihydro-Hildebrandt acid) were isolated from the urine of treated 
animals (Fischer and Bielig, 1940; Asano and Yamakawa, 1950). In both rabbits and rats, the ω-
hydroxylation is mediated by the cytochrome P450 system and requires NADPH and oxygen. It has been 
demonstrated that not only rat liver microsomes are capable of ω-hydroxylating geraniol, but also rat lung 
and kidney microsomes (JECFA, 2004b). 
Unlike geraniol, digeranyl ether does not have free hydroxyl groups to facilitate other routes of 
biotransformation, therefore this would increase the likelyhood that ω-oxidation will occur. 
It would be anticipated that following ω-oxidation the resulting metabolites will undergo glucuronidation 
and be excreted in the urine in a similar way to the aliphatic saturated tertiary alcohols found in FGE.18, 
Revision 1 (EFSA, 2009a) and the non-polar hydrocarbons found in FGE.25Rev2 (EFSA, 2011k). 
III.4. Summary and Conclusions 
The candidate substances are aliphatic, alicyclic or aromatic ethers. On the basis of their structures they can 
be divided into seven subgroups: 1) aliphatic ethers [FL-no: 03.015, 03.016 and 03.022], 2) alicyclic ethers 
[FL-no: 03.008 and 13.200], 3) alicyclic hydrocarbons with an ether side chain [FL-no: 02.247, 02.248 and 
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03.020], 4) benzyl ethers [FL-no: 03.011 and 03.012], 5) phenol ethers [FL-no: 04.059, 04.067, 04.068, 
04.069, 04.079, 04.084, 08.127 and 09.687], 6) naphthol ethers [FL-no: 04.075] and 7) long chain aliphatic 
ethers [FL-no: 03.024]. 
No data on absorption, distribution, metabolism or elimination are reported for the 20 candidate substances. 
According to the available data on supporting substances, the aliphatic ethers in subgroup 1 [FL-no: 03.015, 
03.016 and 03.022], the cyclic ethers in subgroup 2 [FL-no: 03.008 and 13.200], the cyclic hydrocarbon with 
ether side chain in subgroup 3 [FL-no: 02.247, 02.248 and 03.020], the benzyl ethers in subgroup 4 [FL-no: 
03.011 and 03.012] and the phenolic ethers in subgroup 5 [FL-no: 04.059, 04.067, 04.068, 04.069, 04.079, 
04.084, 08.127 and 09.687] and the long chain aliphatic ether in subgroup 7 [FL-no: 03.024] are all expected 
to be rapidly absorbed from the gastrointestinal tract and excreted in the exhaled air as CO2 and as polar 
metabolites in the urine.  
After absorption, the supporting substance, beta-naphthyl methyl ether [FL-no: 04.033], representative for 
the ether in subgroup 6, 1-methoxynaphthalene [FL-no: 04.075], is hydroxylated and excreted as a 
glucuronide. 
Concerning their biotransformation, it can be expected that the straight-chain aliphatic ethers included in the 
subgroup 1 may undergo O-dealkylation in vivo, catalysed by P450 to yield the corresponding alcohol and 
aldehyde that subsequently undergo complete oxidation in the fatty acid pathway and tricarboxylic acid 
cycle. The demethylated product of 1-methoxy-1-decene [FL-no: 03.022] is an enol, which will rearrange to 
the aldehyde, which subsequently can be oxidised to the carboxylic acid. 
On the basis of information on representative supporting substances, the candidate alicyclic ether 2-acetoxy-
1,8-cineole [FL-no: 03.008] and 5-isopropyl-2,6-diethyl-2-methyltetrahydro-2H-pyren [FL-no: 13.200] 
within subgroup 2 may be anticipated to undergo ring-hydroxylation by P450 and conjugation with 
glucuronic acid followed by excretion in the urine. 
The available data suggest that the substance in subgroup 3, alpha-Terpinyl methyl ether [FL no: 03.020] 
would be metabolised by P450 isoenzymes to yield polar hydroxylated metabolites, which are excreted as 
glucuronic acid conjugates or further oxidised and then excreted. Cleavage of the ether is a minor metabolic 
pathway (JECFA, 1999a). The JECFA considered the metabolism of alpha-terpineol at their 51st meeting and 
they concluded that in humans and animals, terpenoid tertiary alcohols are conjugated primarily with 
glucuronic acid and are excreted in the urine and faeces. Unsaturated terpenoid alcohols may undergo allylic 
oxidation to form polar diol metabolites, which may be excreted either free or conjugated. The acetal moiety 
in vanillin 3-(l-menthoxy)propane-1,2-diol acetal [FL-no: 02.248] is shown to be hydrolysed, resulting in the 
formation of the corresponding ether and vanillin. It is expected that the alcoholgroups in this ether 
subsequently are oxidised and that the carboxylic acid(s) are conjugated and then excreted or are excreted as 
the acid itself. Similarly, l-menthoxy ethanol [FL-no: 02.247] is anticipated to be oxidised to the 
corresponding carboxylic acid and excreted. 
The benzyl ethers found in subgroup 4 [FL-no: 03.011 and 03.012] are expected to be metabolised in a 
similar way to mono alkyl derivatives of benzene. It is generally accepted that mono-alkyl derivatives of 
benzene are metabolised by biotransformation of the side chain to produce alcohols and carboxylic acids, 
which are eliminated in the urine as conjugates of glucuronic acid or glycine (Williams, 1959a).  
The candidate aromatic ethers in subgroup 5 [FL-no: 04.059, 04.067, 04.068, 04.069, 04.079, 04.084, 08.127 
and 09.687] are expected to be metabolised by ring-hydroxylation (mainly in the para position, cleavage of 
the methyl ether (O-demethylation) and/or oxidation of the ring substituents depending on the position of 
substituents. These products would then be expected to be conjugated primarily with glucuronic acid and to a 
lesser extent sulphate or glycine and excreted in the urine. 2-(4-Methoxyphenoxy)propionic acid [FL-no: 
08.127] is expected to be excreted as such or after conjugation. 
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The naphthol ether [FL-no: 04.075] in subgroup 6 is expected to be excreted as a glucuronic acid conjugate 
with the methyl ether linkage intact.  
Whilst no metabolism data have been found for the candidate substance in subgroup 7, digeranyl ether [FL-
no: 03.024], data are available on substances that are supporting for the metabolism of longer chain ethers. 
Tsuji et al., concluded that dealkylation of ethers becomes less likely as the chain length increases and that 
ω-oxidation is more likely to occur (Tsuji et al., 1978). The JECFA reviewed the safety of geraniol in 2004 
(JECFA, 2004b) and they concluded that ω-oxidation of geraniol was a common metabolic pathway and that 
this would result in metabolism to innocuous products. EFSA agreed with this view in FGE 72 (EFSA, 
2010d). As digeranyl ether contains no free hydroxyl group like geraniol, other pathways for metabolism of 
geraniol are not available for digeranyl ether and therefore ω-oxidation is more likely to occur. It would be 
expected that following ω-oxidation, the metabolites would be conjugated with glucuronide and excreted in 
the urine. 
It can be anticipated that the 20 candidate substances [FL-no: 02.247, 02.248, 03.008, 03.011, 03.012, 
03.015, 03.016, 03.020, 03.022, 03.024, 04.059, 04.067, 04.068, 04.069, 04.075, 04.079, 04.084, 08.127, 
09.687 and 13.200] are metabolised to innocuous products. Although saturation of some metabolic pathways 
have been described, it occurs at very high doses, unlikely to be reached by the candidate substances when 
used as flavourings at the estimated levels of intakes. 
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ANNEX IV: TOXICITY 
Oral acute toxicity data are available for one candidate substance of the present Flavouring Group Evaluation from chemical groups 15, 16, 22, 26 and 30, and 
for 20 supporting substances evaluated by the JECFA at the 51st, 59th and 61st meeting (JECFA, 1999a; JECFA, 2003a; JECFA, 2004b). The supporting 
substances are listed in brackets. 
 
TABLE IV.1: ACUTE TOXICITY 
Chemical Name [FL-no] Species  Sex  Route  LD50 
(mg/kg bw)  
Reference  Comments 
(Anisole [04.032]) Rat M, F Oral 3700 (Taylor et al., 1964)  
 Rat M, F Oral 3700 (Bär and Griepentrog, 1967)  
 Rat M, F Oral 3700 (Jenner et al., 1964)  
(1-Methoxy-4-methylbenzene [04.015]) Rat M, F Oral 1920 (Wong and Hart, 1971)  
(1,3-Dimethyl-4-methoxybenzene [04.063]) Rat M, F Oral > 2000 (Gilman, 1997)  
(1,3-Dimethoxybenzene 04.016]) Rat NR Oral 2500 (Moreno, 1978l)  
 Rat M, F Oral 2560 (Bär and Griepentrog, 1967)  
(1,4-Dimethoxybenzene [04.034]) Rat NR Oral 3600 (Moreno, 1973ae)  
(Prenyl ethyl ether [03.019]) Mouse M Oral 24 hours:  
1000 – 8000 ;  
14 days:  
1000 – 4000 
(Bähler and Bonetti, 1983)  
Ethyl geranyl ether [03.015] Rat NR Oral > 5000 (Moreno, 1977ag)  
(1,4-Cineole [03.007]) Rat NR Oral 3100 (Moreno, 1981c)  
(1,8-Cineole [03.001]) Rat M, F Oral 2480 (Bär and Griepentrog, 1967)  
 Rat M, F Oral 2480 (Jenner et al., 1964)  
 Rat M, F Oral 1550 (Brownlee, 1940)  
(3,6-Dihydro-4-methyl-2-(2-methylprop-1-en-1-yl)-2H-pyran 
[13.088]) 
Rat NR Oral ~ 5000 (Moreno, 1980l)  
(2,2,6-Trimethyl-6-vinyltetrahydropyran [13.094]) Rat M, F Oral 2700 (Sauer-Freeman, 1980)  
 Mouse NR Oral 4000 – 8000 (Roure Bertrand Dupont, 1979)  
(2-(2-Methylprop-1-enyl)-4-methyltetrahydropyran [13.037]) Rat NR Oral 4300 (Opdyke, 1976)  
(2-Methoxyethyl benzene [03.006]) Rat NR Oral 4100 (Moreno, 1977ah)  
(1-Methoxy-4-propylbenzene [04.039]) Rat M, F Oral 4400 (Taylor et al., 1964)  
 Rat M, F Oral 4400 (Jenner et al., 1964)  
 Rat M, F Oral 4400 (Bär and Griepentrog, 1967)  
 Mouse NR Oral 7300 (Jenner et al., 1964)  
(2- Methoxynaphthalene [04.074]) Rat NR Oral > 5000 (Levenstein, 1974h)  
 Mouse M, F Oral 825 (Schafer and Bowles, 1985)  
(beta-Naphthyl ethyl ether [04.033]) Rat M, F Oral 3110 (Wong and Weir, 1971c)  
 Mouse M, F Oral 1213 (Schafer and Bowles, 1985)  
(Isobutyl beta-naphthyl ether [04.054]) Rat M, F Oral 5930 (Jenner et al., 1964)  
 Rat NR Oral > 5000 (Moreno, 1978m)  
 Rat M, F Oral 5930 (Bär and Griepentrog, 1967)  
(2-Phenoxyethyl isobutyrate [09.487]) Rat NR Oral > 5000 (Moreno, 1973i)  
(Phenoxyacetic acid [08.049]) Rat M, F Gavage 1800 (Burdock and Ford, 1990b)  
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TABLE IV.1: ACUTE TOXICITY 
Chemical Name [FL-no] Species  Sex  Route  LD50 
(mg/kg bw)  
Reference  Comments 
 Rat M, F Gavage 1772 (Piccirillo, 1983)  
 Rat NR Oral > 5000 (Moreno, 1976o)  
(alpha-Terpineol [02.014]) Rat NR Oral 43001 (Moreno, 1971)  
 Mouse M Gavage 2830 (Yamahara et al., 1985)  
(Terpineol acetate [09.830]) Rat M, F Gavage 5075 (Jenner et al., 1964)  
M = Male; F = Female.  
NR = Not reported.  
1 Reported for a mixture of alpha- and beta-terpineol. 
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Subacute / subchronic / chronic / carcinogenicity toxicity data are available for none of the candidate substances of the present Flavouring Group Evaluation 
from chemical groups 15, 16, 22, 26 and 30 but for 10 supporting substances evaluated by the JECFA at the 51st, 61st meeting (JECFA, 1999a; JECFA, 
2004b). The supporting substances are listed in brackets. 
TABLE IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
Chemical Name [FL-no] Species; Sex 
No./Group 
Route Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
(1-Methoxy-4-methylbenzene 
[04.015]) 
Rat; M, F 
20 
Gavage 40, 120, 240 
mg/kg bw/day 
28 days 40 (Brunsborg et al., 1994) 1. 
 Rat; M, F 
10 
Gavage 100, 300, 1000 
mg/kg bw/day 
28 days 
(4 weeks) 
100 (BASF, 1995)  
(Carvacryl ethyl ether [04.038]) Rat; M, F 
10 
Diet 22 mg/kg bw/day 14 days M: < 22  
F : 22 
(Gill and Van Miller, 
1987b) 
1. 
(1,2-Dimethoxybenzene [04.062]) Rat; M, F 
10 
Diet 10 mg/kg bw/day 14 days 10 (Trimmer et al., 1992) 1. 
(1,3-Dimethoxybenzene [04.016]) Rat; M, F 
30 
Diet M: 9.6 mg/kg 
bw/day 
F: 11.2 mg/kg 
bw/day 
90 days M: 9.6  
F: 11.2 
(Oser et al., 1965) 1. 
 Rat; M, F Diet  84 days 
(12 weeks) 
10 (Bär and Griepentrog, 
1967) 
1. 
 Rat; M, F 
20 or 40 
Diet 0.1 and 0.5 % 
equivalent to 50, 
250 mg/kg 
bw/day 
730 days 
(2 years) 
250  (Bär and Griepentrog, 
1967) 
1. 
(1,4-Dimethoxybenzene [04.034]) Rat; M, F 
5 or 10 
Diet 2 % in diet 
equivalent to 
1000 mg/kg 
bw/day 
28 or 56 days 1000 (Altmann et al., 1985) 1. 
(1,8-Cineole [03.001]) Rat; M, F 
12 
Gavage 150, 300, 600, 
1200 mg/kg 
bw/day 
28 days M: 300  
F: 1200 
(NTP, 1987c) 1. 
 Rat; M, F 
12 
Diet 3750, 7500, 
15000, 30000 
ppm equal to 381, 
766, 1740, 3342 
mg/kg bw/day for 
males and 353, 
765, 1527, 3516 
mg/kg bw/day for 
females 
28 days M: Not established  
F: 1500 
(NTP, 1987c) 1. 
 Mouse; M, F 
12 
Gavage 150, 300, 600, 
1200 mg/kg 
bw/day 
28 days 1200 (NTP, 1987d) 1. 
Liver/body weight ratio:  
1. vehicle effect males 20 % increase, 
females 8 % decrease.  
2. inconclusive dose-response 
relationship. 
 Mouse; M, F Diet 3750, 7500, 28 days M: 562.5 (NTP, 1987d) 1. 
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TABLE IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
Chemical Name [FL-no] Species; Sex 
No./Group 
Route Dose levels Duration NOAEL 
(mg/kg bw/day) 
Reference Comments 
12 15000, 30000 
ppm equal to 600, 
1322, 2448, 5607 
mg/kg bw/day for 
males and 705, 
1532, 3152, 6777 
mg/kg bw/day for 
females  
F: 1125 
 Mouse; M 
52 
Gavage 8, 32 mg/kg 
bw/day 
560 days 32 (Roe et al., 1979) 1. 
The mice were dosed with a mixture of 
substances which also included 
chloroform and peppermint oil. This 
study is of limited value as only a small 
number of organs were studied for 
histopathological changes. 
(2-(2-Methylprop-1-enyl)-4-
methyltetrahydropyran [13.037]) 
Rat; M, F 
20 - 32 
Diet M: 2.514 mg/kg 
bw/day 
F: 2.805 mg/kg 
bw/day 
90 days M: 2.514 
F: 2.805 
(Posternak et al., 1969) 1. 
(1-Methoxy-4-propylbenzene 
[04.039]) 
Rat; M 
20 
Gavage Initial dose 2000, 
gradually increase 
to 5000 mg/kg 
bw/day 
32 days Not established (Hagan et al., 1967) 1. 
 Rat; M, F 
20 
Diet  133 days 
(19 weeks) 
Not established (Hagan et al., 1967) 1 . 
(beta-Naphthyl ethyl ether [04.033]) Rat; M, F 
30 
Diet M: 5.1 mg/kg 
bw/day 
F: 5.7 mg/kg 
bw/day 
90 days M: 5.1 
F: 5.7 
(Oser et al., 1965) 1. 
 Rat; NR Diet  84 days 
(12 weeks) 
5.0 (Bär and Griepentrog, 
1967) 
1. 
(Terpineol acetate [09.830]) Rat; M, F 
20 
Diet 0, 1000, 2500 or 
10,000 ppm, 
equivalent to 0, 
50, 125 or 500 
mg/kg bw/day 
140 days 
(20 weeks) 
500 (Hagan et al., 1967) 2. 
Very limited details provided. 
 
M = Male; F = Female.  
NR = Not reported.  
1 Summarised by JECFA 61st  meeting (JECFA, 2004b). 
2 Summarised by JECFA 51st  meeting (JECFA,1999a). 
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Developmental and reproductive toxicity data are available for none of candidate substances of the present Flavouring Group Evaluation from chemical 
groups 15, 16, 22, 26 and 30 but for two supporting substances evaluated by the JECFA at the 59th and 61st meeting (JECFA, 2003a; JECFA, 2004b). 
Supporting substance listed in brackets. 
TABLE IV.3: DEVELOPMENTAL AND REPRODUCTIVE TOXICITY STUDIES 
Chemical Name [FL-no] Species/ Sex 
No./ group 
Route Dose 
Levels 
Duration NOAEL (mg/kg 
bw/day), Including 
information of 
possible maternel 
toxicity 
Reference Comments 
(1,8-Cineole [03.001]) Rat / F 
12 – 17 
Gavage 0.16, 0.8, 1.6 ml/kg 
 
Developmental toxicity 
Gestation days 
9 – 14 
Maternal: 0.8 ml/kg 
Foetal: 0.8 ml/kg 
 
(Hasegawa and Toda, 1978) 1 
The test substance was 
Rowachol®, a mixture of 
α/β-pinene (17 %), l-
menthol (32 %), menthone 
(6 %), borneol (5 %), d-
camphene (5 %), 1,8-cineole 
(eucalyptol) (2 %), and 
rheochrysin (0.1 %). 
(Phenoxyacetic acid [08.049]) Mouse / F  
11 / 8 or more 
Gavage Single dose of 800-900 
mg/kg bw on on of 
days  8 - 15 of 
gestation 
or  
three doses of 250 - 
300 mg/kg bw at 
gestation days 7 - 9, 10 
- 12 or 13 - 15 
Developmental toxicity: 
One dose (Gestation days 8 - 15) or  
three doses  
(Gestation days 7 - 9, 10 - 12 or 13 - 15) 
Maternal: NR  
Foetal: 300 and 900 
(Hood et al., 1979) 2. 
F = Female. 
NR = Not reported. 
1 Summarised by JECFA 61st  meeting (JECFA, 2004b). 
2 Summarised by JECFA 59th  meeting (JECFA, 2003a). 
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In vitro mutagenicity/genotoxicity data are available for three candidate substances of the present Flavouring Group Evaluation from chemical groups 15, 16, 
22, 26 and 30 and for 15 supporting substances evaluated by the JECFA at the 51st, 59th and 61st meeting (JECFA, 1999a; JECFA, 2003a; JECFA, 2004b). 
Supporting substances are listed in brackets. 
TABLE IV.4: GENOTOXICITY (IN VITRO) 
Chemical Name [FL-no] Test System Test Object Concentration 
 
Result Reference Comments 
(Anisole [04.032]) Ames reverse mutation 
assay 
(plate incorporation 
method) 
S. typhimurium TA98, 
TA100, TA1535, TA1537 
3 µmol/plate Negative 
 (+/- S9) 
(Florin et al., 1980) 2. 
 Sister chromatid exchange Human lymphocytes 0 - 2 mM Negative 
 (-S9 only) 
(Jansson et al., 1988) 2. 
(1-Methoxy-4-methylbenzene 
[04.015]) 
Ames reverse mutation 
assay 
(plate incorporation 
method) 
S. typhimurium TA98, 
TA100, TA1535, TA1537 
3 µmol/plate Negative 
(+/- S9) 
(Florin et al., 1980) 2. 
Published non-GLP study. Limited report of study 
details. Validity of the study cannot be evaluated. 
 Ames reverse mutation 
assay 
S. typhimurium TA98, 
TA100, TA1535, TA1537, 
TA1538 
50 mg/plate Negative 
(+/- S9) 
(Heck et al., 1989) 2. 
Published non-GLP study. Some important details 
of study design and results are not reported. Thus, 
the validity of the study cannot be evaluated. 
 Unscheduled DNA 
synthesis 
Rat hepatocytes 188 µg/ml Positive (Heck et al., 1989) 2. 
Published non-GLP study. No information 
concerning the number of concentrations tested. 
Due to the lack of some important details of study 
design and results the validity of the study cannot be 
evaluated. 
(1,2-Dimethoxybenzene [04.062]) Ames reverse mutation 
assay 
S. typhimurium  
TA100 
0.1, 1, 10 and 1000 
µg/plate 
Negative (Rapson et al., 1980) 2. 
(1,3-Dimethoxybenzen [04.016]) Ames reverse mutation 
assay 
S. typhimurium TA98, 
TA100, TA1535, TA1537, 
TA1538 
3.6 mg/plate Negative 
(+/- S9) 
(Wild et al., 1983) 2. 
(1,4-Dimethoxybenzene [04.034]) Ames reverse mutation 
assay (preincubation 
method) 
S. typhimurium TA98, 
TA100, TA1535, TA1537 
10 - 900 µg/plate Negative 
(+/- S9) 
(Haworth et al., 1983) 2. 
 Ames reverse mutation 
assay 
S. typhimurium TA98, 
TA100, TA1535, TA1537, 
TA1538 
5000 ng/plate Negative 
(+/- S9) 
(CIT) . 
1,2,3-Trimethoxybenzene [04.084] Ames reverse mutation 
assay  
S. typhimurium TA98, 
TA100, TA1535, TA1537 
3 µmol/plate Negative 
(+/- S9) 
(Florin et al., 1980) Tested quantitatively with TA100. Published non-
GLP study. Limited report of study details. No 
results reported. Validity of the study cannot be 
evaluated. 
 SOS Chromotest E. coli PQ37 NR Negative (Ohshima et al., 1989) Study assessing the SOS-inducing potency of a 
range of phenols after nitrosation in vitro in the 
absence of metabolic activation. The result for 
1,2,3-trimethoxybenzene was negative. 
(1,8-Cineole [03.001]) Ames reverse mutation 
assay 
S. typhimurium TA97, TA98, 
TA100, TA102 
250 - 2500 µg/plate Negative 
(+/- S9) 
(Gomes-Carneiro et al., 
1998) 
2. 
Published non-GLP study. Fairly detailed 
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TABLE IV.4: GENOTOXICITY (IN VITRO) 
Chemical Name [FL-no] Test System Test Object Concentration 
 
Result Reference Comments 
description of study details and results, generally 
follows OECD guidelines. Study considered valid. 
 Ames reverse mutation 
assay (preincubation 
method) 
S. typhimurium TA98, 
TA100, TA1535, TA1537 
3.3 - 3333 µg/plate Negative 
(+/- S9) 
(Haworth et al., 1983) 2. 
Published summary report including detailed results 
from studies on 250 compounds tested in various 
laboratories within the NTP to a large extent in 
accordance with OECD guideline 471. 
 Sister chromatid exchange Chinese hamster ovary cells 50 - 500 µg/ml
600 - 800 µg/ml 
Positive (-S9) 
Negative (+S9) 
(Galloway et al., 1987a) 2. 
Lowest dose to give a significant increase in SCE: 
Trial I – 500 µg/ml; Trial II – 200 µg/ml. Published 
non-GLP study. Doses were selected based on 
preliminary assay.  Some details of results are not 
reported. Test was positive only without activation 
and at doses that induced cell cycle delay. 
 Sister chromatid exchange Chinese hamster ovary K-1 
cells 
10, 33.3 and 100 µM Negative 
(-S9 only) 
(Sasaki et al., 1989) 2. 
Published non-GLP study of limited quality. Study 
designed to investigate the influence on 
spontaneous as well as on mitomycin-induced SCEs. 
 Chromosomal aberration 
assay 
Chinese hamster ovary cells 479 - 663 µg/ml 
630 - 810 µg/ml 
Negative  
(+/- S9) 
(Galloway et al., 1987a) 2. 
Published non-GLP study. Doses were selected 
based on preliminary assay. Although some details 
of results are not reported the study is considered 
valid. No aberration induction was detected even 
after extending the incubation time without S9 to 20 
hrs. 
 Rec assay B. subtilis H17 (rec+) and 
M45 (rec-) 
18 µg/disk Negative (Oda et al., 1979) 2. 
Study published in Japanese without English 
abstract. Data extracted from tables. Validity of the 
study cannot be evaluated. The SOS chromotest is 
not considered predictive for genotoxicity. 
 Rec assay B. subtilis H17 (rec+) and 
M45 (rec-) 
20 µl/disk  
(20,000µg/disk) 
Negative (Yoo, 1986) 2. 
Study published in Japanese with English abstract. 
Data extracted from tables. Validity of the study 
cannot be evaluated. The SOS chromotest is not 
considered predictive for genotoxicity. 
(1-Methoxy-4-propylbenzene 
04.039]) 
Ames reverse mutation 
assay 
S. typhimurium TA98, 
TA100, TA1535, TA1537, 
TA1538 
750 µg/plate Negative 
(+/- S9) 
(Wild et al., 1983) 2. 
 Unscheduled DNA 
synthesis 
Rat hepatocytes 5 x 10-3 M Negative (Howes et al., 1990) 2. 
(2-Methoxynaphthalene [04.074]) Ames reverse mutation 
assay 
(plate incorporation 
method) 
S. typhimurium TA98, 
TA100, TA1535, TA1537 
3 µmol/plate Negative 
(+/- S9) 
(Florin et al., 1980) 2. 
(beta-Naphthyl ethyl ether 
[04.033]) 
Ames reverse mutation 
assay 
S. typhimurium TA98, 
TA100, TA1535, TA1537, 
TA1538 
3.6 mg/plate Negative 
(+/- S9) 
(Wild et al., 1983) 2. 
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TABLE IV.4: GENOTOXICITY (IN VITRO) 
Chemical Name [FL-no] Test System Test Object Concentration 
 
Result Reference Comments 
 Ames reverse mutation 
assay 
(plate incorporation 
method) 
S. typhimurium TA98, 
TA100, TA1535, TA1537 
3 µmol/plate Negative 
(+/- S9) 
(Florin et al., 1980) 2. 
(Isobutyl beta-naphthyl ether 
[04.054]) 
Ames reverse mutation 
assay 
S. typhimurium TA98, 
TA100, TA1535, TA1537, 
TA1538 
1 mg/plate Negative 
(+/- S9) 
(Wild et al., 1983) 2. 
(2-Phenoxyethyl isobutyrate 
[09.487]) 
Ames reverse mutation 
assay 
S. typhimurium TA98, 
TA100, TA1535, TA1537, 
TA1538 
3600 µg/plate Negative 
(+/- S9) 
(Wild et al., 1983) 3. 
(Phenoxyacetic acid [08.049]) Mutagenicity assay S. cerevisiae  D7tsl 16 mM Negative  
(- S9) 
(Venkov et al., 2000)  
(Alpha-terpineol [02.014]) Ames test S. typhimurium 
TA98, TA100, TA1535, 
TA1537, TA1538 
10000 µg/plate Negative (Heck et al., 1989) 4. 
 Ames test S. typhimurium 
TA97a, TA98, TA100, 
TA102 
2500 µg/plate Negative1 (Gomes-Carneiro et al., 
1998) 
 
 Ames test S. typhimurium 
TA98, TA100, TA1535, 
TA1537, TA1538 
1000 µg/plate Negative 
(+/- S9) 
(National Cancer Institute, 
1983) 
4. 
 Spot test S. typhimurium TA98, 
TA100, TA1535, TA1537 
3 µg/plate 
(463 µg/plate) 
Negative 
(+/- S9) 
(Florin et al., 1980) 4. 
 Mammalian cell mutation Mouse Lymphoma  
L5178Y TK +/- 
0.5 µl/ml (467µg/ml) 
0.75µl/ml (700 µg/ml) 
Negative (- S9) 
Negative (+S9) 
(Kirby et al., 1984)  
 Mammalian cell mutation Mouse Lymphoma  
L5178Y TK +/- 
300 nl/ml (280 µg/ml)  
250 nl/ml (233 µg/ml) 
Negative 
(+/- S9) 
(Heck et al., 1989) 4. 
 Rec assay S. cerevisiae NR Negative 
(+ S9) 
(Oda et al., 1979) 4. 
(Terpineol acetate [09.830]) Rec assay B. subtilis  
H17, M45 
19 µg Negative (Oda et al., 1979) 4. 
Vanillin 3-(l-menthoxy)propane-
1,2-diol acetal [02.248] 
Ames test S. typhimurium  
TA98, TA100, TA1535, 
TA1537 
Up to 5000 µg/plate Negative 
(+/- S9) 
(Kajiura, 1996b) The study is not completely in accordance with 
OECD guidelines (471): no confirmation of 
negative findings in an independent experiment and 
only two plates per concentration. 
 Ames test E. coli WP2 uvrA Up to 5000 µg/plate Negative 
(+/- S9) 
(Kajiura, 1996b) The study is not completely in accordance with 
OECD guidelines (471): no confirmation of 
negative findings in an independent experiment and 
only two plates per concentration. 
5-Isopropyl-2,6-diethyl-2-
methyltetrahydro-2H-pyran 
[13.200] 
 S. typhimurium  
TA98, TA100,TA102, 
TA1535, TA1537 
Up to 5000 µg/plate Negative 
(+/- S9) 
(Thompson, 2008) Valid GLP study. 
 
(Tetrahydro-4-methyl-2-(2-
methylpropen-1-yl)pyran [FL-no: 
13.037) 
 S. typhimurium  
TA98, TA100,TA102, 
TA1535, TA1537 
Up to 5000 µg/plate Negative 
(+/- S9) 
(Verspeek-Rip, 2002b) Valid GLP study. 
1 A slight but dose-related response was noted with TA102 with and without the use of metabolic activation.  
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2 Summarised by JECFA 61st  meeting (JECFA, 2004b). 
3 Summarised by JECFA 59th  meeting (JECFA, 2003a). 
4 Summarised by JECFA 51st  meeting (JECFA, 1999a). 
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In vivo mutagenicity/genotoxicity data are available for none of the candidate substances of the present Flavouring Group Evaluation from chemical groups 
15, 16, 22, 26 and 30 but for six supporting substances evaluated by the JECFA at the 59th and 61st meeting (JECFA, 2003a; JECFA, 2004b). Supporting 
substances are listed in brackets.  
TABLE IV.5: GENOTOXICITY (IN VIVO) 
Chemical Name  Test System Test Object  Route Dose Result  Reference  Comments 
(1,3-Dimethoxybenzene [04.016]) In vivo Micronucleus test Mouse Intraperitoneal 
injection 
558, 966 or 1382 mg/kg bw Negative (Wild et al., 1983) 1. 
In vivo Sex- linked 
recessive lethal mutation 
assay 
D. melanogaster  25 mM Negative (Wild et al., 1983) 1. 
In vivo Micronucleus test Mouse Oral gavage 2000 mg/kg bw Negative (Hoechst, 1996)  
(1,4-Dimethoxybenzene [04.034]) 
 
In vivo Micronucleus test Mouse Intraperitoneal 
injection 
750, 1125 or 1500 mg/kg Negative (Wild et al., 1983)  
(1-Methoxy-4-propylbenzene 
[04.039]) 
In vivo Sex- linked 
recessive lethal mutation 
assay 
D. melanogaster (751 µg/ml) 5 mM Negative 
(+/- S9) 
(Wild et al., 1983) 1. 
 In vivo Micronucleus test Mouse Intraperitoneal 
injection 
1500 mg/kg Negative 
 
(Wild et al., 1983) 1. 
(beta-Naphthyl ethyl ether [04.033]) In vivo Micronucleus test Mouse Intraperitoneal 
injection 
344, 603 or 861 mg/kg bw Negative (Wild et al., 1983) 1. 
 In vivo Sex- linked 
recessive lethal mutation 
assay 
D. melanogaster  25 mM Negative (Wild et al., 1983) 1. 
(Isobutyl beta-naphthyl ether 
[04.054]) 
In vivo Micronucleus test Mouse Intraperitoneal 
injection 
800, 1400 or 2000 mg/kg bw Negative (Wild et al., 1983) 1. 
In vivo Sex- linked 
recessive lethal mutation 
assay 
D. melanogaster  25 mM  Negative (Wild et al., 1983) 1. 
(2-Phenoxyethyl isobutyrate 
[09.487]) 
In vivo Micronucleus 
formation assay 
Mouse bone marrow 
cells 
Intraperitoneal 
injection 
1875 mg/kg/bw Negative (Wild et al., 1983) 2. 
In vivo Sex-linked 
recessive mutation 
D. melanogaster  10 mM  Negative (Wild et al., 1983)  
1 Summarised by JECFA 61st  meeting (JECFA, 2004b). 
2 Summarised by JECFA 59th  meeting (JECFA, 2003a). 
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ABBREVIATIONS 
ADI  Acceptable Daily Intake 
AUC  Area Under Curve 
BW  Body Weight 
CAS  Chemical Abstract Service 
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
Chemical Abstract Service 
CHO  Chinese hamster ovary (cells) 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
EC European Commission 
EFFA  European Flavour and Fragrance Association 
EFSA  The European Food Safety Authority 
EROD  EthoxyRresorufin-O-Deethylase 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
GI   GastroiIntestinal 
ID   Identity 
IOFI  International Organization of the Flavour Industry 
IR   Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
LD50  Lethal Dose, 50%; Median lethal dose 
MC  MethylCholanthrene 
MROD  MethoxyResorufin-O-Demethylase 
MS  Mass spectrometry 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
MTBE  Methyl Tertiary-Butyl Ether 
NAD  Nicotinamide Adenine Dinucleotide  
NADP  Nicotinamide Adenine Dinucleotide Phosphate 
NADPH Nicotinamide Adenine Dinucleotide Phosphate, reduced form 
No  Number 
NOAEL No Observed Adverse Effect Level 
NOEL  No Observed Effect Level 
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NTP  National Toxicology Program 
PB  PhenoBarbital 
PROD  PentoxyResorufin-O-Depenylase 
SCE  Sister Chromatid Exchange 
SCF  Scientific Committee on Food 
SMART  Somatic Mutation and Recombination Test  
MTBE  Methyl Tertiary-Butyl Ether  
TAMDI Theoretical Added Maximum Daily Intake 
TBA  Tertiary-Butyl Alcohol 
UDS  Unscheduled DNA Synthesis  
WHO  World Health Organisation  
